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ABSTRACT 
 
Ulcerative colitis is a chronic inflammation of the large intestine, and it may 
increase risk of human colorectal cancer. Polyphenolics from mango and pomegranate 
have been shown to have potent anti-inflammatory properties, thus they could be the 
potential therapeutic agents for colitis. However, the mechanism underlying these effects 
of polyphenolics has not yet been elucidated.  
To determine the anti-inflammatory effects and possible mechanisms of 
polyphenolics from mango (gallic acid and gallotannins), and pomegranate (ellagic acid 
and ellagitannins) in dextran sodium sulfate (DSS)-induced colitis in rats, Sprague 
Dawley rats were administered control, mango, or pomegranate juice, and were exposed 
to three cycles of 3% DSS followed by 2-week recovery period. Colon inflammation and 
injury scores were assessed, and cell proliferation was evaluated by 
immunohistochemical detection of Ki-67. The mRNA and protein expressions involved 
in the inflammatory response and the mTOR pathway were analyzed by qRT-PCR, low 
density arrays, western blot analysis and multiplex bead assay. The involvement of 
miRNAs was additionally investigated with the antagomiR-126 and antagomiR-145 in 
lipopolysaccharide (LPS)-treated CCD-18Co, non-cancer colon fibroblasts cell lines.  
Both mango and pomegranate showed anti-inflammatory properties in vitro and 
in vivo. Mango and pomegranate juice reduced DSS-induced colon inflammation score 
(41% and 50%) and cell proliferative index (38% and 36%) during chronic colitis in rats 
compared to control juice. Mango and pomegranate juice significantly attenuated the 
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pro-inflammatory cytokines, CRP, TNF-, IL-1, GM-CSF, and IL-6 levels in colonic 
tissues. In addition, mango and pomegranate juice suppressed COX-2 and iNOS mRNA 
and protein expressions. Mango juice suppressed HIF-1 by decreasing the 
PI3K(p85)/AKT-mTOR signaling axis via up-regulation of miR-126, while 
pomegranate decreased p70S6K and HIF-1 by up-regulating miR-145. The interactions 
of mango with miR-126/PI3K(p85) and pomegranate with miR-145/p70S6K1 were 
additionally identified in CCD-18Co cells, where mango and pomegranate extract 
reversed the effect of the antagomiR.  
In addition, the modulation of microbiota composition (Blautia, Fusobacterium, 
and Ruminococcaceae) by pomegranate and short-chain fatty acids (SCFA; Isovalerate 
and valerate) production by mango may be involved in at least in part the anti-
inflammatory effects of polyphenolics.  
These results suggest that both mango and pomegranate polyphenolics seem to 
have potential in the prevention and mitigation of colon inflammation.  
 
 iv 
 
ACKNOWLEDGEMENTS 
 
I would like to thank Dr. Susanne Talcott for providing me with advice and 
encouraging me to develop independent thinking and research skills throughout this 
research, and Dr. Joanne Lupton for her continuing kind support. I am also very grateful 
to Dr. Clinton Allred, Dr. Jan Suchodolski, and Dr. Ivan Ivanov for their guidance and 
support.  
I wish to thank Dr. Nancy Turner for her valuable guidance and advice during 
my doctoral work, and Dr. Stephen Talcott for encouraging me to do my best. A big 
thank also to Yasushi Minamoto and Melissa Markel for helping me with the 
measurement of microbiota and short chain fatty acids, and Zlatomir Zlatev for 
providing me the software for gene expression analysis. 
I want to extend my gratitude to Nivedita Banerjee, Dr. Luciana Azevedo, Stella 
Taddeo, and Youngmi Cho for their support and friendship. I also appreciate the 
incredible help from my labmates: Kimmy Krenek, Shirley Arbizue, and Sunday Simbo 
for helping me in several steps of my research. I would like to thank Andrea Roque, 
Matthew Nemec, Enrique Garcia Perez, Paula Cipriano, Manoela Dias, Dr. Hercia 
Martino for their constant support and for sharing memorable and fun times in the lab. 
A special thank go to my beloved parents, Mr. Joohyun Kim and Mrs. Jungsook 
Kim, and my younger sister, Myungsoo Kim, for their support and for praying for me.  
Finally, I would like to thank God for always being there for me.  
 v 
 
TABLE OF CONTENTS 
 Page 
ABSTRACT .................................................................................................................. ii 
ACKNOWLEDGEMENTS .......................................................................................... iv 
TABLE OF CONTENTS ............................................................................................... v 
LIST OF FIGURES ..................................................................................................... vii 
LIST OF TABLES ........................................................................................................ ix 
CHAPTER I  INTRODUCTION AND LITERATURE REVIEW .................................. 1 
Ulcerative colitis ........................................................................................................ 1 
mTOR pathway ........................................................................................................ 13 
Polyphenolics........................................................................................................... 16 
Advances in disease-specific methodologies and models .......................................... 26 
Summary and project overview ................................................................................ 31 
Hypothesis ............................................................................................................... 34 
Objectives ................................................................................................................ 34 
CHAPTER II  MANGO POLYPHENOLICS REDUCE INFLAMMATION IN 
INTESTINAL COLITIS - POTENTIAL INVOLVEMENT OF THE MIR-
126/PI3K/AKT/MTOR PATHWAY IN VITRO AND IN VIVO ................................. 35 
Summary ................................................................................................................. 35 
Introduction ............................................................................................................. 36 
Materials and methods ............................................................................................. 39 
Results ..................................................................................................................... 45 
Discussion ............................................................................................................... 55 
CHAPTER III  POMEGRANATE POLYPHENOLICS REDUCE 
INFLAMMATION IN INTESTINAL COLITIS - POTENTIAL INVOLVEMENT 
OF THE MIR-145/P70S6K/HIF1-PATHWAY IN VITRO AND IN VIVO .............. 61 
Summary ................................................................................................................. 61 
Introduction ............................................................................................................. 62 
Materials and methods ............................................................................................. 64 
Results ..................................................................................................................... 70 
Discussion ............................................................................................................... 80 
 vi 
 
CHAPTER IV COMPARISON OF ANTI-INFLAMMATORY MECHANISMS OF 
MANGO (MANGIFERA INDICA L.) AND POMEGRANATE (PUNICA 
GRANATUM L.) IN DSS-INDUCED COLITIS ......................................................... 86 
Summary ................................................................................................................. 86 
Introduction ............................................................................................................. 87 
Materials and methods ............................................................................................. 89 
Results ..................................................................................................................... 93 
Discussion ............................................................................................................. 102 
CHAPTER V  MANGO AND POMEGRANATE POLYPHENOLICS IN THE 
MODIFICATION OF MICROBIOTA AND SHORT CHAIN FATTY ACIDS IN 
DSS-INDUCED COLITIS ......................................................................................... 106 
Summary ............................................................................................................... 106 
Introduction ........................................................................................................... 107 
Materials and methods ........................................................................................... 110 
Results ................................................................................................................... 114 
Discussion ............................................................................................................. 120 
CHAPTER VI  SUMMARY AND CONCLUSION ................................................... 124 
REFERENCES .......................................................................................................... 128 
 
 
 vii 
 
LIST OF FIGURES 
 Page 
Figure 1. Etiology of inflammatory bowel disease (IBD) (Kaser A et al, 2010) (5)......... 2 
Figure 2. Short chain fatty acids produced in GI tract. .................................................... 6 
Figure 3. The immune dysregulation during ulcerative colitis (Danese S et al, 2011) 
(28). ................................................................................................................ 8 
Figure 4. The mTOR signaling pathway (Zhang YJ et al, 2009) (57)............................ 14 
Figure 5. Chemical structure of (A) gallic acid and (B) gallotannin. ............................. 19 
Figure 6. Chemical structure of (A) ellagic acid and (B) punicalagin (ellagitannins)..... 21 
Figure 7. Biodegradation pathway for gallotannins and ellagitannins (Li M et al, 
2006) (109). .................................................................................................. 26 
Figure 8. Experimental design. ..................................................................................... 41 
Figure 9. Representative chromatographic profile at 280nm of phenolic compounds in 
mango juice (Keitt) and the daily liquid consumption by rats. ....................... 46 
Figure 10. Effects of mango juice on DSS-induced colonic inflammation (A) and 
colonocyte proliferation (B, C) in DSS-treated rats. ...................................... 48 
Figure 11. Effects of mango juice on pro-inflammatory cytokines, NF-B, COX-2 
and iNOS in DSS-treated rats. ....................................................................... 49 
Figure 12. Effects of mango juice on the mTOR signaling pathway in DSS-treated 
rats. ............................................................................................................... 51 
Figure 13. Effects of mango extract on the inflammatory and the mTOR signaling 
pathway in LPS-treated CCD-18Co cells. ..................................................... 53 
Figure 14. Effects of mango extract on miR-126 and PI3K mRNA levels in 
transfected CCD-18Co cells with a miR-126 antagomiR. .............................. 56 
Figure 15. Experimental design. ................................................................................... 66 
Figure 16. Representative chromatographic profiles at 280nm, 360nm and 520nm of 
phenolic compounds in pomegranate juice (POM wonderful) and the daily 
liquid consumption by rats. ........................................................................... 72 
 viii 
 
Figure 17. Effects of pomegranate juice on DSS-induced colonic inflammation and 
ulceration (A) and colonocyte proliferation (B) in DSS-treated rats. .............. 74 
Figure 18. Effects of pomegranate juice on pro-inflammatory cytokines, COX-2 and 
iNOS in DSS-treated rats. ............................................................................. 75 
Figure 19. Effects of pomegranate juice on the mTOR signaling pathway in DSS-
treated rats. ................................................................................................... 77 
Figure 20. Effects of pomegranate extract on the inflammatory and the HIF1-
signaling pathway in LPS-treated CCD-18 cells......................................... 79 
Figure 21. Effects of pomegranate extract on miR-145 and p70S6K1 mRNA levels in 
in LPS-treated CCD-18 cells. ........................................................................ 81 
Figure 22. Effects of mango and pomegranate juice on DSS-induced colonic 
inflammation and ulceration in rats. .............................................................. 94 
Figure 23. Proteomic profiling altered by mango and pomegranate juice in DSS 
treated rats. ................................................................................................... 95 
Figure 24. miRNAs expression altered by mango and pomegranate juice in DSS 
treated rats. ................................................................................................... 97 
Figure 25. Differentially expressed genes involved in the mTOR signaling altered by 
mango or pomegranate juice. ........................................................................ 99 
Figure 26. Differentially expressed genes involved in the MAPK pathway altered by 
mango or pomegranate juice. ...................................................................... 101 
Figure 27. Correlation analysis of total or phosphorylated protein abundance and 
mRNA expression. ...................................................................................... 102 
Figure 28. Effects of mango and pomegranate juice on CRP and pro-inflammatory 
cytokines in serum and DSS-induced colitis. ............................................... 115 
Figure 29. The influence of mango and pomegranate juice on microbiota. ................. 116 
Figure 30. SCFAs production by mango and pomegranate juice ................................. 117 
Figure 31. The level of TLR4, MyD88, GRP43, and GRP41 mRNA altered by mango 
and pomegranate juice. ............................................................................... 118 
Figure 32. Gene expressions related to lactate metabolism and autophagy altered by 
mango and pomegranate juice. .................................................................... 120 
 ix 
 
LIST OF TABLES 
 Page 
 
Table 1. Microbiota of the GI-tract (Hakansson A et al, 2011) (16). ............................... 4 
Table 2. Effects of pomegranate on chemically-induced inflammation in intestinal in 
vivo models. .................................................................................................. 23 
Table 3. Effects of mango juice on final body weight, food intake, juice intake, and 
caloric intake. ............................................................................................... 47 
Table 4. Effects of pomegranate juice on final body weight, food intake, juice intake, 
and caloric intake. ......................................................................................... 71 
Table 5. The nutritional analysis for the experimental juices. ....................................... 90 
Table 6. Differentially expressed genes in the mTOR pathway by mango and 
pomegranate juice. ........................................................................................ 98 
Table 7. Differentially expressed genes in the MAPK pathway by mango and 
pomegranate juice. ...................................................................................... 100 
 1 
 
CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Inflammatory bowel disease (IBD) is an inflammatory condition of the GI tract. 
There are two main subtypes of IBD: Crohn's disease (CD) and ulcerative colitis (UC). 
They have similar symptoms, but they may also have certain differences. The 
differences between CD and UC are the location, pathology, and radiology of the 
inflammatory response. UC is characterized by a chronic and relapsing inflammation of 
the mucosal layer of the large intestine, which includes the colon and rectum. In CD, 
inflammation extends deep into the bowel wall of any part of the gastrointestinal tract. In 
addition, UC is a symmetrical, continuous inflammation causing shallow ulcers, while 
CD is discontinuous and occurs in patches with deep ulcers with strictures and fistulae. 
UC has a higher incidence than CD (1, 2). 
 
Ulcerative colitis  
In UC, the inflammation causes loss of the lining of the colon, leading to rectal 
bleeding, diarrhea, and occasional abdominal pain, as well as fever and weight loss in 
severe cases, and it is associated with an increased risk for human colorectal cancer. The 
frequency of UC has increased since the mid-20th century. UC has an incidence of 1 to 
20 cases per 100,000 people per year, and it has a prevalence of 8 to 246 per 100,000 
people. The highest incidence and prevalence are shown in the populations of the United 
States, Canada, and the United Kingdom, while it is rare in Asia. 1.4 million people in 
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the United States and 2.2 million people in Europe suffer from UC, and it usually first 
occurs in people between 15 and 30 years of age, but there is a second peak between the 
ages of 55 and 80. This disease appears equally in men and women (3).  
 
Etiology 
IBD is a multifactorial condition, and the development of this disease is affected 
by four factors: genetic susceptibility, gut microbiota imbalance, immune dysregulation, 
and environmental factors (e.g., smoking and diets high in fat and sugar) (Figure 1) (3-
5).  
 
 
Figure 1. Etiology of inflammatory bowel disease (IBD) (Kaser A et al, 2010) (5).  
Polymorphisms shared between CD and UC are shown in black, genes specific for CD 
are shown in magenta, and genes specific for UC are shown in blue. 
Microbiota 
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Genetic susceptibility 
IBD is considered a polygenic disorder, and twin and family studies have 
indicated that the inheritable factor is stronger in CD than in UC (6). Genome-wide 
searches for IBD susceptibility loci identified genes (IBD1-9 locus) that contribute to 
IBD susceptibility. In initial screenings, the nucleotide binding oligomerization domain 
2 (NOD2/CARD15; IBD1 locus) gene on chromosome 16 was identified as a CD 
susceptibility gene. It was reported that variants of the NOD1 and NOD2 elevated the 
NF-κB activation and the IL-1 and IL-18 secretion (7). In addition, autophagy genes 
(ATG16L1) and intelectins (ITLN1) were confirmed to be specific for CD, whereas 
immune regulators (IL-10 and ARPC2) and dysfunction of the intestinal epithelial cells 
(ECM1) were specific to UC (Figure 1) (8, 9). A sequence variant in IL-10 induced a 
risk of developing UC near 35% (10), and IL-10 knockout mice developed clinical and 
histologic features similar to human UC (11). In addition, genes involved in the IL-23 
signaling (IL23R, IL12B, JAK2, STAT3) were related to both CD and UC (5). 
 
Microbiota imbalance 
An aberrant ratio of protective to aggressive microbiota in the large intestine 
results an inappropriate immune response, which can lead to IBD, irritable bowel 
syndrome, and colon cancer. The microbiota are integral in triggering and enhancing 
IBD. It was shown that germfree mice had no evidence of UC (12), and the use of 
antibiotics and prebiotics caused the remission of IBD (13). There are more than 1014 
microbiota, from more than 1000 species, in the gastrointestinal tract, mostly in the 
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colon. There will be 100-1000 fold more anaerobes than aerobes. Some of the 
microbiota are permanent residents in the gut, while others are altered by diet or 
environment. Microbiota are important for colon health, as they protect against 
pathogens and are important in the induction of immune regulatory functions and in 
processing nutrients into short chain fatty acids (SCFAs) (14).  
Most microbiota are gram-negative Bacteroidetes (about 20%) and gram-positive 
Firmicutes (about 80%; mainly composed of Clostridia), while the remainder are 
Actinobacteria (3%), Proteobacteria (1%), Verrucomicrobia (0.1%), viruses, protists 
and fungi (Table 1) (15, 16). Among the levels of genus, Bacteroides is the most 
abundant genus in the gut microbiota, followed by Faecalibacterium, Bifidobacterium, 
and Lactobacillus (17).  
 
Table 1. Microbiota of the GI-tract (Hakansson A et al, 2011) (16). 
Phyla Class Family Genus Gram 
Firmicutes 
 
 
 
 
 
Bacteroidetes 
Fusobacteria 
Proteobacteria 
Actinobacteria 
Bacilli 
 
 
Clostridia 
 
 
Bacteroidia 
Fusobacteria 
Grammaproteobacteria 
Actinobacteria 
Streptoccaceae 
Lactobacillaceae 
Turicibacteraceae 
Ruminococcaceae 
 
Clostridiaceae 
Bacteroidaceae 
Fusobacteriaceae 
Enterobacteriaceae 
Bifidobacteriaceae 
Streptococcus 
Lactobacillus 
Turicibacter 
Ruminococcus 
Faecalibacterium 
Blautia 
Bacteroides 
Fusobacterium 
Escherichia coli 
Bifidobacterium 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
+ 
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Microbiota activate the immune system to produce reactive oxidative stress 
(ROS) or cytokines, and they are involved in the development of inflammatory disease 
and colon cancer, partly though the induction of the toll-like receptors 
(TLR)s/MyD88/NF-κB signaling pathway (18). Gram-negative bacteria (Bacteroides, 
Fusobacterium, and Escherichia coli) contain lipopolysaccharide (LPS) as the major 
component in the cell membrane. The TLR family is located on the cell surface and in 
endosomes, and the stimulation of TLRs by LPS triggers an inflammatory response 
through myeloid differentiation primary response 88 (MyD88) and NF‐κB activation and 
overproduction of pro‐inflammatory cytokines, such as TNF- and IL-6 (19, 20). 
Bifidobacterium and Lactobacillus are considered to be probiotics that induce health 
benefits, and exert anti-inflammatory properties through inhibition of NF‐κB activation 
and IL‐8 secretion (21). Other gram-positive bacteria (Ruminococcaceae, Blautia, 
Faecalibacterium, and Streptococcus) were also shown to have anti-inflammatory 
effects, as the production of SCFAs blocked NF-κB activation and the induction of IL-
10 (22).  
SCFAs are a sub-group of fatty acids with 2 to 6 carbons, primarily acetate, 
propionate, butyrate, and valeric acid (Figure 2). The level of SCFAs in the gut depends 
on the amount of non-digestible oligosaccharides in the diet and the composition of the 
microbiota (23). SCFAs are metabolites produced from undigested carbohydrates, fibers, 
proteins and polyphenols by protective microbiota, and they seem to be beneficial in the 
suppression of inflammatory responses and UC (24). 
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Figure 2. Short chain fatty acids produced in GI tract. 
 
 
 
SCFAs are an energy source for colonic epithelial cells, and they play a role in 
the maintenance of colonic barrier integrity and function. Acetate inhibits 
enteropathogenic bacteria by reducing pH, while propionate reduces fatty acid and 
cholesterol biosynthesis in the liver (25). SCFAs, such as acetate, propionate, and 
especially butyrate bind the G-protein coupled receptor 43 (GPR43, FFAR2) or GRP41 
(FFAR3). SCFA endogenous receptor interaction is necessary for the suppression of 
inflammatory responses, as it decreases the production of pro-inflammatory cytokines 
(IL-1β, TNF-α, IL-12, IL-17, inducible protein (IP)-10), increases the production of anti-
inflammatory cytokine IL-10, and suppresses the activation of various immune cells 
such as macrophages, eosinophil, T cells, B cells, and dendritic cells (24, 26).  
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Immune dysregulation 
The gut consists of the epithelial barrier (enterocytes, goblet cells, 
enteroendocrine cells, paneth cells, and M cells), stromal/fibroblast cells, and the 
mucosal immune system (T and B lymphocytes, dendritic cells, macrophages, and 
neutrophils) which exchange signals via the production of mediators. The gut 
homeostasis maintains a controlled innate immune response to the microbiota, which is 
binding on the transmembrane TLRs and the nucleotide-binding oligomerization 
domain-like receptors (NLRs) on the epithelial and immune cells. Upon binding the 
pathogens, TLR signaling (mainly TLR4) induces MyD88, transforming growth factor –
 activated kinase 1 (TAK1), and NF-B expression for antimicrobial defense (27). 
However, when the immune system is damaged in the colonic mucosa, uncontrolled 
immune responses impair the gut’s epithelial barrier. Glycolipids and bacteria induce the 
up-regulation of interleukin-13 receptor α2 (IL-13 α2) in mucosal natural killer T cells. 
The activation and feedback loop of IL-13 causes epithelial-barrier dysfunction, 
resulting in increased permeability. This leads to bacteria invading the mucosal barrier 
directly to generate antibacterial antibodies. Exposure of macrophages, neutrophils and 
dendritic cells to the microbiota triggers the activation of TLRs and NLRs, which 
induces the production of pro-inflammatory cytokines and chemokines (e.g., IL-1β, IL-6, 
IL-8, IL-17, IL-23, MIP-2, MRP-14, MMP-1, and TNF-) (Figure 3) (28, 29). 
Abnormal adaptive immunity occurs, such that IgM, IgA, and IgG levels are elevated, 
and the aberrant responses of naïve CD4+ T cells are divided into Type 1 helper T cells 
(Th1 cell-mediated response; CD) and Type 2 helper T cells (atypical Th2 response; 
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UC). CD4+ T cells are essential regulators of the immune response. Induction of Th1 in 
CD increases the interferon-IFN), TNF, and lymphotoxin production that is critical 
for cell-mediated immunity, whereas the atypical Th2 response in UC produces 
abundant IL-4, IL-5, IL-10, and IL-13, which induces epithelial cell damage, apoptosis, 
and epithelial barrier dysfunction. The balance of Th1 and Th2 causes the differentiation 
between UC and CD (30).  
 
 
Figure 3. The immune dysregulation during ulcerative colitis (Danese S et al, 2011) 
(28). 
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Environmental factors 
Environmental factors, such as an unhealthy diet, stress and smoking history, 
may trigger the development of UC by influencing the composition of the gut microbiota 
or disrupting the intestinal barrier. Among these factors, dietary factors may highly 
influence on colitis development and progression. Diets high in dietary fiber, vitamin D, 
and n-3 polyunsaturated fatty acids (PUFA) help decrease intestinal inflammation. It was 
reported that soluble fiber from fruits and vegetables was protective against colitis 
through fermentation into SCFAs by gut microbiota, whereas non-fermentable insoluble 
fiber from grain intake did not reduce colitis (31). Vitamin D is an immune system 
regulator, and its deficiency is related to UC (32). Vitamin D receptors have been 
identified on almost cells involved in immune system, and vitamin D affects 
inflammation through modulation of the Th1 and Th2 pathway (33). Arachidonic acid 
(AA) is the precursor in the eicosanoids production. Intake of n-3 PUFAs has been 
reported to decrease the production of inflammatory eicosanoids, cytokines, and reactive 
oxidative stress through replacing AA in inflamed cell membrane and inhibiting AA 
metabolisms (34). In addition, n-3 PUFAs alters the expression of inflammatory gene 
through the modulation of transcription factors during colitis (35). However, western-
style diets characterized by a high fat, high protein, n-6 PUFAs, and low consumption of 
fruits and vegetables, are known to trigger colitis. High fat diet induced colonic 
inflammation through modulation of natural killer T cells and regulatory T cells in colitis 
(36). Cohort studies reported that high animal protein intake was associated with the 
induced risk of IBD (37). A high intake of n−6 PUFAs induced the eicosanoids 
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production, which is an important mediator to produce pro-inflammatory cytokines (34). 
In addition, a high intake of alcohol increased the risk of developing UC (38). The 
relationship between UC and smoking is complex. Former smokers are associated with a 
high risk of UC; however, it has been shown that nicotine can be used as a therapeutic 
agent for UC treatment (39). 
 
Increased risk of colorectal cancer 
The most serious complication of UC is the high risk of developing human 
colorectal cancer (40). The risk of colorectal cancer increases with the duration of the 
disease, with a cancer risk of 2% after 10 years, 8% after 20 years, and 18% after 30 
years, and it has high mortality (> 50%) (41, 42). The risk factors for developing colon 
cancer include the long duration of colitis (more than 8 years), a young age at onset, 
severe inflammation, and a family history of colorectal cancer (28). 
The activated inflammatory cells (neutrophils and macrophages) in colitis 
generate large amounts of ROS and reactive nitrogen intermediates (RNI). The ROS 
induces DNA damage and mutation in adjacent epithelial cells and releases pro-
inflammatory cytokines such as TNF-, IL-6, and IFN-and causes tissue injury and 
destruction in mucosal epithelial cells (43). Activation of the DNA damage results in 
epigenetic changes that induce oncogenes and suppress tumor suppressor genes, which 
leads to telomere shortening and the induction of senescence in cells. Senescent cells are 
also characterized by an increase of pro-inflammatory cytokines, which contribute to 
mutagenesis in the epithelial cells, and can lead to dysplasia and carcinogenesis (44). 
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Treatment 
Conventional treatment of colitis 
Since UC is a major risk factor for colorectal cancer, interventions for UC can 
potentially decrease the morbidity and mortality associated with human colorectal 
cancer. The medical or surgical treatment of UC depends on the extent of the disease. 
Mild to moderate UC responds to drugs, such as anti‐inflammatory drugs (sulfasalazine, 
5-aminosalicylic acid (5-ASA; Mesalamine, Olsalazine, and Balsalazide) or 
corticosteroids (Prednisone)), antibiotics (Metronidazole, Ciprofloxacin, and Rifaximin), 
and/or immunosuppressive drugs (Azathioprine, Methotrexate, Cyclosporine, or 
Infliximab) (45).  
5-ASA and corticosteroids, as anti-inflammatory agents, are first line therapies to 
decrease inflammation in mild to moderate UC, and they have a remission rate of about 
50%. 5-ASA is available in oral forms and in enemas, and it is prescribed in a 
combination of these two forms (up to 4.8g per day). Mesalamine shows the best clinical 
response in patients with mild UC. Corticosteroids are generally used in people who did 
not respond to 5-ASA, as it has a number of side effects, such as weight gain, mood 
swings, high blood pressure, and diabetes.  
Antibiotics and immunosuppressive drugs (Cyclosporine, Infliximab) are used in 
patients who do not respond to 5-ASA or after remission is achieved in severe UC. 
These drugs not only treat inflammation but also target the immune system. However, 
these agents still have serious side effects and clinical limitations for in terms of use. 
Among these drugs, Infliximab is increasingly used due to its effectiveness and better 
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short-term safety compared with other therapies. Infliximab is a monoclonal antibody 
against TNF-and it works by removing TNF- in patients with moderate to severe 
UC. If these medications do not work, surgery to remove part of the colon is needed 
(colectomy) (46). 
 
Alternative nutritional treatments 
The use of nutritional components has become an attractive approach for treating 
UC, particularly with those who fail to respond to medical therapies or have concerns 
about the side effects. Similar to medical therapies, natural compounds are used as anti-
inflammatory agents and immunomodulators, and they include prebiotics, essential fatty 
acids, and polyphenolics (47). The benefits of prebiotics are that they are safe for the 
host, genetically stable, capable of surviving passage through the gastrointestinal tract, 
and they produce SCFAs from bacterial fermentation in the colon. Unlike CD, UC may 
respond to probiotics, and the most common probiotics used in UC are Bifidobacteria, 
Lactobacillis, the E. coli strain Nissle 1917, and VSL#3 which contains several species 
of Bifidobacteria, Lactobacillus, and Streptococcus (13). These species can prevent 
colonization of pathogenic bacteria by producing SCFAs and antimicrobial compounds 
(Bacteriocins), and by inducing immune regulatory responses (48). n-3 polyunsaturated 
fatty acids result in potent anti-inflammatory agents by inhibiting arachidonic acid 
metabolism and altering the expression of inflammatory genes (34).  
Polyphenols are known for their antioxidant properties, which depend on 
chemical structures that allow them to trap, quench or scavenge ROS, therefore 
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preventing oxidative DNA damage (49). Some studies show that polyphenolics, such as 
quercetin, quercitrin, genistein, theaflavin-3,3’digallate, thearubigin, curcumin, 4-
coumaric acid, ellagic acid, resveratrol, and piceatannol, lowered UC severity in vivo via 
suppression of the NF-κB signaling cascade and reduction of the pro-inflammatory 
mediators (50). For example, quercetin suppressed UC in DSS-treated rats through 
inhibition of NF-κB activation and reduction of iNOS (51, 52). Curcumin also lowered 
UC through suppression of NF-κB signaling and the down-regulation of iNOS and 
COX-2 expression in TNBS-treated rats. IL-10 expression was increased by curcumin 
(53, 54). The consumption of fruits and vegetables rich in polyphenolics should be a 
therapeutic strategy for preventing and managing UC.  
 
mTOR pathway 
The mammalian target of rapamycin (mTOR) pathway plays a central role in the 
regulation of cell proliferation, anti-apoptosis and inflammation that lead to the 
induction of carcinogenesis. The name is derived from the inhibitor rapamycin, which 
was isolated from a soil bacterium (55). In the immune system, it is known that the 
stimulation of T and B cell receptors, cytokine receptors, and TLRs leads to the 
activation of the mTOR pathway. During the early stages of UC, LPS from bacteria and 
IFNs from activated mucosal T cells may trigger the signal transduction of NF-B and 
the mTOR pathway (56). Once phosphatidylinositol 3-kinase (PI3K) is activated by 
insulin, IGF-1, or TLR4, it starts a signal transduction cascade via the protein SER/Thr-
kinase (AKT) and the mTOR. mTOR exists in two complexes within the cell: mTOR 
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complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Activation of mTORC1 
regulates protein synthesis (HIF1), cell growth, and cell proliferation via downstream 
transduction of proliferative signals, such as 4E-BP1 and p70S6K, which phosphorylates 
the ribosomal protein S6 (Figure 4) (57).  
 
 
Figure 4. The mTOR signaling pathway (Zhang YJ et al, 2009) (57). 
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It is well documented that the mTOR pathway plays an important role during 
tumorigenesis (58). Currently, there is increasing evidence of the link between mTOR 
activity and inflammation. Cytokines, growth factors, insulin, and LPS stimulation cause 
the activation of p70S6K1 and 4EBP1, which are down-stream targets of the mTOR 
pathway (56). Moreover, LPS treatment induced the mTOR pathway and NO 
production, and it activated STAT1 dependent transcription in macrophages (59). 
Several studies showed that mTOR inhibitors suppressed experimental murine colitis by 
inhibiting T cell function and blocking IFN- release (60-62). Targeted suppression of 
these activated pathways during colitis using natural compounds provides an important 
strategy for colitis and colon cancer prevention.  
 
miRNAs targeting the mTOR pathway 
microRNAs (miRNAs) are emerging as potential post-transcriptional regulators 
for the regulation of inflammatory and immune responses (63). miRNAs are a class of 
small, non-coding RNA molecules in length of 5-20 nucleotides (nt) that bind to 
sequences located in the 3′-untranslated region of target mRNAs and regulate mRNA 
degradation or repress their translation (64). Inflammatory cytokines and microbiota 
components induce expression of miRNAs such as miR-146 and miR-155, via the NF-
κB pathway in myeloid cells (65, 66). It has been shown that miR-146 modulates TLRs 
and TNF-α signaling pathways by reducing the expression of Interleukin-1 receptor-
associated kinase 1 (IRAK1), TNF receptor-associated factor 6 (TRAF6), and COX-2 
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(65). miR-155 is shown to regulate adaptive immune responses, such as antigen 
presentation and T cell receptor signaling (67).  
The mTOR pathway is a promising target of miRNAs for anti-colitis and anti-
cancer therapeutics (68). miR-126 has a target site in the promoter region of the 
phosphatidylinositol 3-kinase regulatory subunit beta (PI3Kp85β), an upstream 
component of the mTOR pathway (64). Accordingly, miR-126 may be a potential 
chemopreventive and anti-inflammatory target via the inhibition of angiogenesis, 
vascular integrity, inflammation, and proliferation (69). miR-145 also has a 
chemopreventive effect through the target of the promoter regions of p70S6K1, a 
downstream target of the mTOR pathway, which regulate cell proliferation, 
inflammation, and angiogenesis (70). Previous studies indicated that the miR-126 and 
miR-145 could provide a rationale for the suppression of the mTOR pathway, and the 
mTOR pathway is a promising target for miRNAs in colitis therapy.  
Recent studies have shown that dietary factors influence miRNA expression. 
Moreover, polyphenolics are known to modulate post-transcriptional regulation by 
regulating the expression of miRNAs (71). 
 
Polyphenolics 
Polyphenolics are secondary metabolites of plants and are characterized 
structurally by the presence of phenol rings. Polyphenolics are produced by the natural 
defense of plants against ultraviolet radiation and insets. The Shikimic acid pathway is 
the main metabolic pathway to synthesize the aromatic compounds, such as tryptophan, 
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phenylalanine, and tyrosine, which serve as the precursors to many phenolic compounds 
(72). More than 8000 phenolic compounds have been identified, and they can be 
classified into four different classes: phenolic acids (hydroxybenzoic acids and 
hydroxycinnamic acids), flavonoids (anthocyanins, flavanols, flavonols, flavones, 
flavanones, and isoflavones), stilbenes, and lignins (73). Polyphenolics are proposed to 
have anti-oxidant, anti-aging, anti-carcinogenic, and anti-inflammatory effects and to 
exert their beneficial effects by reducing the oxidative stress and inhibiting pro-
inflammatory cytokines through the modulation of NF-κB, COX-2, and iNOS activity in 
an inflamed colon (74, 75). However, even though the anti-inflammatory activity of 
individual polyphenolics has been shown, the combination of a variety of polyphenolics 
in fruits and vegetables might have a synergistic effect with regard to UC prevention 
(76). 
 
Mango (Mangifera indica L.)  
Mango (Mangifera indica L.) is one of the most cultivated tropical fruits 
consumed worldwide. It has mainly been cultivated in South Asia, but currently mango 
is commercially grown in almost 87 countries ranking fifth in total production among 
major fruit crops. Its chemical composition varies according to the location of 
cultivation, variety, and stage of maturity. Mango is a good source of dietary fiber 
(pectin and cellulose), vitamin C, ß-carotene, calcium, iron, and phenolic compounds 
(77). In this study, mango was peeled to remove skin and seed, and only the pulp was 
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homogenized and centrifuged for removing fiber and producing the experimental mango 
juice. The mango juice contained sugar, vitamin C, and polyphenolics.  
Among over 30 different varieties of mango, Alphonso is the most popular 
variety due to its strong aroma, thin skin, delicious taste, and high nutritive value (78). In 
the US, Ataulfo, Haden, Keitt, Kent, and Tommy Atkins are the major mango cultivars 
(79). In this study, the Keitt variety has been used.  
 
Polyphenolics in mango  
Mango is rich in polyphenols, such as gallic acid, gallotannins, flavonoids 
(quercetin and kaempferol), benzophenone derivatives, and mangiferin. These 
polyphenolics are distributed in the different parts of the mango (pulp, seed kernel, peel, 
leaves and bark), and the concentration of bioactive compounds varies according to 
variety or cultivar, environmental factors, harvest conditions, and processing (77). Gallic 
acid is a tribydroxibenzoic acid found in both free form and as part of gallotannins, and 
it is the most predominant polyphenolic in mango. Gallotannins are compounds formed 
when gallic acid binds with the hydroxyl group of a polyol carbohydrate such as glucose 
(Figure 5) (80). 
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Figure 5. Chemical structure of (A) gallic acid and (B) gallotannin. 
 
 
 
Mango polyphenolics in inflammation 
Mango polyphenolics may protect against UC by exhibiting anti-inflammatory 
properties. Gallic acid is known to have antioxidant, anti-inflammatory, and anti-cancer 
effects (77, 81), and gallotannins are also considered to be the major antioxidant 
polyphenols found in mango (80). Vimang, a stem bark extract of the mango that is used 
in Cuba, showed anti-inflammatory activity through inhibition of PGE2 (82), TNF and 
NO in in vivo and in vitro experiments (83). It was reported that mango extract has anti-
inflammatory properties via the reduction of iNOS, COX-2, TNF and TNFR-2 in a 
DSS-induced rat colitis model (84).  
The PI3K/AKT pathway is well-established upstream regulators of mTOR. 
Gallic acid has been shown to have anti-inflammatory and chemopreventive effects 
through the down-regulation of PI3K/AKT pathway and NF-B activity in gastric cancer 
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cells (85). Lupeol is a triterpene found in mango, and it showed chemopreventive effects 
through the down-regulation of PI3K/AKT pathway and NF-B activity in skin 
carcinogenesis in mice (86). Thus, mango may modulate the mTOR pathway through 
suppression of the PI3K/AKT pathway.  
For the reasons described above, mango is a potential source of polyphenolics 
with anti-inflammatory properties that could be used to reduce and/or prevent the 
incidence of UC.  
 
Pomegranate (Punica granatum L.) 
Pomegranate (Punica granatum L.) is oriented in the Mediterranean region and 
India, and it has been used for medicinal purposes. Currently, it is mainly cultivated in 
India, Spain, China, and some parts of the US. Pomegranate is consumed fresh or in 
processed form as juice, wines, and extracts. It is a good source for dietary fiber, vitamin 
C, vitamin K, and polyphenols (87, 88). In this study, the pomegranate juice mainly 
contained sugar and polyphenolics. 
 
Pomegranate polyphenolics in inflammation 
Pomegranate is rich in polyphenols, such as ellagic acid, ellagitannins 
(punicalagins and punicalins), flavonoids (quercetin, kaempferol, and luteolin 
glycosides), and anthocyanins (cyanidin, delphinidin, and pelargonidin glycosides) (89). 
About 124 phytochemicals have been identified in the pomegranate (90). 
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Ellagic acid is a polyphenolic found in fruits and nuts such as pomegranates, 
raspberries, strawberries, and walnuts, and it is found either in a free form or bound as 
ellagitannins. Punicalagin is a unique form in pomegranates, and it is a type of 
ellagitannin (Figure 6) (91). Flavonoids are classified into flavonols (quercetin and 
kaempferol), flavones (apigenin), flavanols (epicatechin and epigallocatechin-3-gallate), 
flavanones (naringenin), and anthocyanidines (cyanidine, delphinidin, and pelargonidin) 
(92). 
 
 
Figure 6. Chemical structure of (A) ellagic acid and (B) punicalagin (ellagitannins) 
 
 
 
Pomegranate and inflammation 
Pomegranate polyphenolics may also protect against UC by exhibiting anti-
inflammatory properties. Ellagic acid inhibited NF-B activity through induction of IkB 
phosphorylation and suppression of reduced IL-8 secretion in Caco-2 cell lines (93), and 
it reduced colitis severity via reduction of MPO and TBARS activity in DSS-treated rats 
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(94). Previously, the anti-inflammatory effects of pomegranate extracts have been 
reported in DSS or trinitrobenzene sulfonic acid (TNBS)-induced colitis rat models 
(Table 2). Dietary pomegranate showed anti-inflammatory activities through inhibition 
of MPO activity and TNF levels. In addition, the diet decreased COX-2 and iNOS 
expression and reduced MAPK pathway (p38MAPK, JNK, and ERK1/2) and NF-B 
activity in chronic TNBS-induced colitis (95, 96). In DSS-induced colitis models, 
pomegranate extract reduced colitis severity via modulation of the microbiota in the gut 
(Bifidobacterium, Lactobacillus, and Clostridium) and the decrease of COX-2, iNOS, 
PTGES, and PGE2 (97).  
The mTOR pathway could be the target of pomegranate polyphenolics. In human 
lung carcinoma cells and lung tumors in mice, pomegranate polyphenols down-regulated 
inflammation by suppressing the PI3K/AKT pathway and decreasing the activation of 
NF-B (98, 99). In addition, pomegranate extracts have been shown to induce 
cytotoxicity and anti-inflammatory properties in colon cancer in vitro and in vivo by 
inhibiting the PI3K/AKT pathway and the activation of NF-B (100-102). The inhibition 
of the PI3K/AKT pathway by pomegranate polyphenolics may modulate the expression 
of mTOR.  
Although pomegranate polyphenolics suppressed inflammatory responses by 
suppressing the PI3K/AKT pathway, the underlying mechanisms and in vivo 
confirmation of their effects, have yet to be elucidated. This study, with respect to 
understanding the abilities and mechanisms of these compounds to suppress 
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inflammation, may provide valuable information about their potential application in 
colitis prevention and therapy. 
 
Table 2. Effects of pomegranate on chemically-induced inflammation in intestinal 
in vivo models. 
Type Dose Inflammatory effects Ref. 
Rats; 
TNBS 
400mg/d Lowered colitis, inhibit TNF-induced priming of NADPH 
oxidase by targeting the p38MAPK and MPO release 
(95) 
Rats; 
TNBS 
250-500mg/kg/d Lowered colitis, reduced TNF and MPO activity, decreased 
iNOS, COX2, MAPK pathway and NF-B 
(96) 
Rats; 
DSS  
200mg/kg/d Lowered colitis, reduced MPO activity (103) 
Rats; 
DSS  
250mg/kg/d Lowered colitis, reduced iNOS, COX-2, PTGES and PGE2 (97) 
 
Absorption and metabolism of polyphenolics 
Pharmacokinetics is the study of the absorption, distribution, metabolism, and 
excretion (ADME) of compounds. The bioavailability of polyphenolics can vary, and the 
absorption and metabolism depend on the parent structure (gallic acid or ellagic acid), 
degree of chemical modification, molecular size, degree of polymerization, and 
solubility. Small molecules, such as gallic acid, are easily absorbed through the gut, but 
larger polyphenolics are very poorly absorbed (104). Polyphenolics have been 
considered to mainly be absorbed in the small intestine due to the high surface area. 
However, it has been reported that a large number of polyphenols pass from the small 
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intestine to the large intestine, which indicates the importance of the colon in polyphenol 
metabolism (105). Polyphenolics that are not absorbed such as gallotannins and 
ellagitannins enter into the colon, where they could be hydrolyzed by gut microbiota to 
low molecular weight polyphenols via esterase, glucosidase, demethylation, 
dehydroxylation and decarboxylation activities (106).  
The metabolism of the gut microbiota on polyphenolics may modify the immune 
response and the potential health effects. Polyphenolics are metabolized by gut 
microbiota in colon, and produce a number of metabolites. Polyphenolics and their 
metabolites can influence the composition and function of the gut microbiota (107). The 
effect of polyphenolics on bacterial growth and metabolism depends on strain, 
polyphenols structure, and dosage. Gram-negative microbiota are more resistant to 
polyphenolics than Gram-positive due to the differences of cell wall composition (108). 
The gut microbiota are considered to be a critical factor in UC. Understanding the 
interactions between the gut microbiota and polyphenolics would be important for 
preventing UC.  
 
Pharmacokinetics of mango polyphenolics 
The predominant polyphenols in mango are gallic acid and gallotannins. In the 
colon, the biodegradation of gallotannins by microbiota leads to the production of gallic 
acid, which is followed by the decarboxylated product, pyrogallol, and the dehydro 
product, resorcinol, as well as a host of other smaller molecular weight compounds 
(Figure 7) (109). Increased levels of Clostridium and Bacteroides are a cause of colitis, 
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and the growth of pathogenic E. coli and Clostridium perfringens was strongly inhibited 
by gallic acid (110). Gallotannins showed anti-microbiota activity against gram-positive 
bacteria except E. coli, Pseudomonas, and lactic acid (111).  
 
Pharmacokinetics of pomegranate polyphenolics 
Pomegranate is rich in ellagic acid and ellagitannins. The biodegradation of 
ellagitannins in the colon produces ellagic acid followed by gallic acid (Figure 7) (109). 
The main metabolite of pomegranate polyphenolics is urolithin-A. After pomegranate 
ellagitannins intake, the level of urolithin-A was increased, and it also facilitated the 
colonization of beneficial bacteria, such as Lactobacilli, Bifidobacterium, and 
Clostridium, which contributed to colonic health (97). The metabolites of polyphenolics 
may have anti-inflammatory effects on the intestinal environment through the 
modulation of the gut microbiota populations.  
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Figure 7. Biodegradation pathway for gallotannins and ellagitannins (Li M et al, 
2006) (109).  
 
Advances in disease-specific methodologies and models 
Currently, at least 66 models of experimental IBD have been developed to 
investigate the etiology of this disease. They have been classified into genetic, 
immunological, bacterial, and chemical models (112). Genetic models, including gene 
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knockout (KO) and transgenic models, are useful for identifying components of the 
immune system that are involved in colitis development (113). Immunological models 
perform the adoptive transfer of host T cells into immunodeficient recipient mice (112). 
Bacterial models use various bacterial strains that are known to induce colitis in 
immunodeficient mice or mice housed under special environmental conditions (germ 
free, specific pathogen free, and gnotobiotic) (114). In chemical models, intestinal 
inflammation was increased by a single intrarectal administration of Oxazolone (4-
ethoxoymethylene-2-phenyloxazol-5-one), TNBS, or dinitrobenzene sulfonic acid 
(DNBS). In addition, an oral administration of DSS, or an intraperitoneal injection of 
LPS also chemically increase inflammation (115, 116). TNBS-induced colitis resembles 
CD and DSS-induced colitis is similar to UC (117). Although these colitis murine 
models have a limited capability to fully recapitulate human colitis, there is still an 
opportunity to test various therapeutic strategies and gain insight into the etiology of the 
disease.  
 
Genetic models 
Most of these models in which targeted genes encoding specific immune factors 
(IL-2, IL-10, TCR, TGF, WASP, SHIP1, TLR5, and MUS2), have been knocked out, 
and they are useful for identifying components of the immune response that are involved 
in IBD development (118). In addition, overexpressing IBD susceptibility genes 
(TNFSF15 and IL-7) have been confirmed to develop IBD (119). IL-10 is a known IBD 
susceptibility gene. IL-10 knockout mice have the colitis caused by enteric microbiota, 
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and many studies with probiotics were performed with this model (116). IL-2 is 
necessary for T cell homeostasis. IL-2 knockout mice develop an autoimmune disease 
characterized by colitis with a massive infiltration of T cells (120). While these genetic 
models recapitulate the histopathological and clinical features associated with human 
IBD, there are many key features in the development of inflammation. These genetic 
models can demonstrate the important interaction between environmental factors and 
genetic predisposition and the crosstalk between intestinal epithelium and mucosal 
immune response systems, which are necessary for maintaining normal homeostasis and 
which can contribute to the development of inflammatory bowel disease.  
 
DSS-induced colitis model  
The DSS-induced colitis model is the most effective in producing the clinical and 
histological features of UC characteristics in experimental animals. DSS is a sulfated 
polysaccharide of dextran that is synthesized by certain bacteria, such as Leuconostoc 
spp and Strptococcus spp from sucrose (121). The molecular weight of DSS ranges from 
5kDa to 1,400kDa. The severity of colitis depends on the different molecular weights. 
DSS of 40kDa can cause the most severe colitis, while DSS of 5kDa or 500kDa 
developed relatively milder colitis (122). Depending on the concentration, the duration, 
and frequency of administration of DSS in the drinking water, acute or chronic colitis 
developed in colon. Clinical manifestation of DSS colitis is bleeding, diarrhea, 
ulcerations, intestinal inflammation, shortening of colon length, and weight loss (123). 
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Histological changes by DSS treatment mainly occur on the mucosa, and can be 
classified as acute and chronic. Acute colitis causes mucin depletion, epithelial 
degeneration, and necrosis of epitherial cells. Chronic colitis induces infiltration of 
lymphocytes and neutrophil, cryptitis, and crypt abscesses (124). Cryptitis is the 
migration of neutrophils to the epithelial lining of mucosa, while crypt abscesses is 
related to the migration of neutrophils into lumen of crypts. Cryptitis and crypt abscesses 
are the main feature of human IBD (121).  
The epithelial barrier injury caused by DSS may lead the colonic mucosal 
permeability, and allows permeation of DSS through loss of tight junction components. 
It was shown that loss and redistribution of the tight junction such as occludin, ZO-1, 
and claudin proteins causes the impairment of epithelial barrier system in acute colitis by 
DSS (125). The response of inflammatory mediators by DSS have been implicated in the 
pathogenesis of human IBD. The expression of inflammatory mediators such as TNF-, 
IFN-, IL-1, and IL-6 are up-regulated, whereas synthesis of anti-inflammatory 
cytokines such as IL-10 are down-regulated in DSS-induced colitis. In addition, DSS –
induced colitis is linked with the induction of nitric oxide and iNOS (126). In particular, 
epithelial homeostasis, regeneration and wound healing in DSS-treated rats is similar to 
human IBD (127). Although the DSS-induced colitis model does not represent the 
complexity of the human disease, it is still a valuable tool for investigating the 
involvement of dietary factors into in pathogenesis of IBD and evaluating different 
therapeutic options (128). 
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AOM/DSS murine model 
Intestinal inflammation is a risk factor of human colorectal cancer, but the 
underlying mechanisms are still unclear. Colon cancer is a multistep process, and the 
combination of azoxymethane (AOM) and DSS induce a similar aberrant crypt foci-
adenoma-carcinoma sequence to human colon cancer. AOM/DSS-induced tumors 
showed several molecular features, such as mutations in the -catenin, K-Ras, p53, c-
Myc and NF-B, and epigenetic modification similar to human colon cancer. This model 
is simple and has high reproducibility and potency, and it is an outstanding model for 
chemopreventive intervention studies (129).  
 
LPS-treated CCD-18Co myofibroblast cells 
Intestinal myofibroblasts CCD-18Co are non-transformed colon cells, and they 
spontaneously become immortalized without transfection. Myofibroblasts are located 
subjacent to the epithelium, and define the structure of tissue microenvironments. In 
addition, they play crucial roles in intestinal inflammation and wound healing through 
the secretion of pro-inflammatory cytokines, prostaglandins, and growth factors (130). 
Intestinal inflammation damages the epithelial barrier systems, allows the penetration of 
pro-inflammatory agents into the lamina propria, and exacerbates the loss of the surface 
epithelial cells. It increases the accumulation of immune cells, such as CD4+ T cells and 
the activation of non-immune cells, such fibroblasts, which then become directly 
involved in immune responses, in the lamina propria (131). In chronic inflammation, 
myofibroblasts respond to the surrounding stimulus, exhibit a stable pro-inflammatory 
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phenotype, which may contribute to chronicity of the inflammation. Myofibroblasts are 
also involved in the repair of epithelial cell monolayers during intestinal inflammation 
(132).  
Myofibroblast cell lines express TLR-4, which is activated by LPS, a component 
of gram-negative bacteria, which subsequently leads to the secretion of pro-
inflammatory mediators (133) and the induction of COX-2, iNOS and prostaglandin 
synthesis (134). It can also secrete large amounts of IL-6, IL-8, M-CSF, and GM-CSF 
upon stimulation. The cytokine profile and the amount of cytokines released suggest that 
colonic myofibroblasts may play a role during mucosal inflammation. Therefore, this 
LPS-treated CCD-18Co myofibroblast cells model can be used to investigate 
mechanisms of inflammation (135).  
 
Summary and project overview 
UC is the most common form of IBD, and it is characterized by a chronic 
inflammation of the mucosal layer of the large intestine (1, 2). Although colitis is rarely 
lethal on its own, people with colitis are at high risk for developing colon cancer (40). 
Hence, there is a need to develop natural therapeutic agents for the prevention and 
treatment of colitis.  
The anti-inflammatory effects of polyphenolics from mango (Mangifera indica 
L.) and pomegranate (Punica granatum L.) have been studied. However, their 
underlying molecular mechanisms are still unclear. The major objective of this research 
is to determine the anti-inflammatory effect of mango and pomegranate polyphenolics 
 32 
 
on ulcerative colitis. In addition, we investigate the specific mechanisms of these natural 
compounds in the inflammatory responses for prevention of intestinal inflammation in 
vivo and in vitro models. 
 The mTOR pathway plays a central role in the regulation of the cell growth, cell 
proliferation, and inflammation that leads to the induction of colitis (136). The 
suppression of the mTOR pathway may play a key role in the anti-inflammatory strategy 
for treating colitis. miRNAs are important post-transcriptional regulators because they 
induce mRNA degradation or block translation, and it may be involved by modulating 
the target mRNA expressions (64). The mTOR pathway is a promising target for 
miRNAs in colitis treatment (68). In addition, microbiota and their metabolite SCFAs 
are beneficial in the suppression of the inflammatory response in the colon. They can 
activate the immune system to suppress ROS or pro-inflammatory cytokines, and the 
TLR4/mTOR signaling pathway can be a target of microbiota and SCFAs to reduce the 
inflammatory response (18).  
Polyphenolics derived from dietary sources are considered sources of natural 
chemopreventive and chemotherapeutic compounds through their antioxidant defense 
systems and anti-inflammatory effect from the suppression of NF-B, COX-2, and iNOS 
activation (74, 75). Previously, we demonstrated that mango polyphenolics inhibited the 
growth of several cancer cells, particular colon cancer cells, by inducing apoptosis and 
reducing ROS generation (81). In addition, gallic acid, the most abundant polyphenol in 
mango, has been shown to have an anti-inflammatory effect by the down-regulation of 
the PI3K/AKT pathway and NF-B activity in colon and gastric cancer cells (85, 93). A 
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previous study demonstrated that pomegranate inhibited cancer growth by inhibiting the 
PI3K/AKT pathway and NF-B activity in colon cancer cell lines (102). Although these 
compounds exhibited anti-inflammatory effects by suppressing the PI3K/AKT pathway 
which is the upstream regulators of the mTOR pathway, the underlying mechanisms and 
in vivo confirmation of their effects, have yet to be elucidated. 
Gene expression analysis can be used to compare the gene expression profiles 
altered by the intake of different polyphenolics in in vivo colitis models. This analysis 
allows us to figure out the potential therapeutic target of the natural compounds for the 
prevention of inflammatory disease and to elucidate the underlying mechanisms by 
which the polyphenolics ameliorate the inflammatory response.  
The development of natural anti-inflammatory products, either as part of a diet or 
as supplements, may be important due to their efficacy, safety, wide availability, and 
good stability. Targeted suppression of activated mTOR pathways during inflammation 
responses by these natural compounds may provide an important strategy for the 
prevention of ulcerative colitis. 
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Hypothesis 
The overall hypothesis is that polyphenolics from mango and pomegranate may 
show anti-inflammatory effects in colitis in vivo and in vitro. Furthermore, polyphenolics 
may suppress cell proliferation and colon inflammation at least in part by modulating the 
AKT/mTOR/HIF1- axis and associated factors.  
 
Objectives 
1) Investigate the mechanisms underlying suppression of the mTOR pathway by 
polyphenolics from mango on colitis - Potential Involvement of the miR-
126/PI3K/AKT/mTOR pathway  
2) Investigate the mechanisms underlying suppression of the mTOR pathway by 
polyphenolics from pomegranate on colitis - Potential Involvement of the miR-
145/p70S6K/HIF1- pathway 
3) Compare the gene expression profiles altered by mango and pomegranate 
polyphenolics on colitis 
4) Determine the role of intestinal microbiota and metabolites changed by mango and 
pomegranate polyphenolics 
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CHAPTER II  
MANGO POLYPHENOLICS REDUCE INFLAMMATION IN INTESTINAL 
COLITIS - POTENTIAL INVOLVEMENT OF THE MIR-126/PI3K/AKT/MTOR 
PATHWAY IN VITRO AND IN VIVO 
 
Summary 
Ulcerative colitis is a chronic inflammation of the large intestine, and it may 
increase risk of human colorectal cancer. Mango polyphenolics such as gallic acid and 
gallotannins have shown antioxidant and anti-inflammatory properties in several studies. 
However, the mechanism underlying these effects is not yet clear.  
The objective of this study was to investigate the potential role of the miR-
126/PI3K/AKT/mTOR signaling pathway in the anti-inflammatory effects of mango 
juice in dextran sodium sulfate (DSS)-induced colitis in Sprague Dawley rats. 
Lipopolysaccharide (LPS)-treated human CCD-18Co colon-myofibroblastic cell lines 
were also used. 
Animals were administered control juice (15.7g sugar and 0.05g citric 
acid/100ml) or mango juice (total phenolic content of 475.80mg/L gallic acid 
equivalents (GAE)), and exposed to three cycles of 3% DSS followed by 2-week 
recovery period. The mRNA and protein levels of pro-inflammatory cytokines and the 
PI3K/AKT/mTOR signaling pathway were measured by RT-PCR, western blot analysis 
and multiplex bead assay in vivo and in vitro. 
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Results showed that mango juice protected against DSS-induced colon 
inflammation and suppressed cell proliferation as measured by Ki-67 staining in rats 
during chronic colitis compared to control juice. The mango juice significantly 
attenuated the expressions of pro-inflammatory cytokines such as tumor necrosis factor 
(TNF)-, IL-1, COX-2 and iNOS at mRNA and protein levels. Moreover, the 
expressions of PI3K, AKT, and mTOR were reduced while miR-126 targeting PI3K 
(p85) was up-regulated by the mango group compared to the control. Similar results 
were observed in LPS and mango extract treated CCD-18Co cell lines. The relationship 
between miR-126 and its target gene PI3K (p85 was confirmed with the further in 
vitro treatment with miR-126 antagomiR.  
These results suggest that mango polyphenols attenuated inflammatory response 
by modulating the PI3K/AKT/mTOR pathway in part though up-regulation of miRNA-
126 expression both in vitro and in vivo, and mango may be a potential therapeutic for 
colitis.  
 
Introduction 
Ulcerative colitis (UC) is a kind of inflammatory bowel disease (IBD) and has a 
close association with human colorectal cancer (43). Long-term chronic inflammation 
produces high levels of pro-inflammatory cytokines and inflammatory molecules, which 
increases the risk of cancer (40). It is suggested that more than 20% of IBD patients 
develop colon cancer within 30 years of disease onset, and have a 50% increased risk for 
mortality (41). Accordingly, anti-inflammatory drugs play an important role in the 
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prevention and treatment of colitis and colorectal cancer (137). Several studies have 
focused on developing natural anti-inflammatory products as part of the diet or from 
supplements due to its efficacy, safety, wide availability and good stability (138). 
Polyphenolics derived from fruits and vegetables are highly considered to be 
sources of natural anti-inflammatory compounds through inhibition of NF-B activation 
and induction of antioxidant defense systems (139). Mango is rich in polyphenols, 
including gallic acid, galloyl derivatives, flavonol glycosides and benzophenone 
derivatives, that exhibit antioxidant and anti-inflammatory properties in master cells and 
lung cancer cells (140-142). Gallic acid, the most abundant polyphenols in mango, has 
been shown the chemopreventive effects by reducing colon carcinogenesis through 
inhibition of oxidative stress and NF-B activation (143, 144). In addition, mango 
extracts were reported to have anti-oxidant (145) and anti-inflammatory activities (82, 
84), and we previously demonstrated that mango extract inhibited the growth of several 
cancer cells, particular colon cancer cells through induction of apoptosis and reduction 
of reactive oxygen species (ROS) generation (81). However, the underlying mechanisms 
relevant to the preventive effects of mango polyphenolics on colitis have not been well 
investigated. 
The mTOR pathway plays a central role in the regulation of cell growth and cell 
proliferation through downstream transduction of proliferative signals, such as 4E-BP1 
and p70S6K1 (57). Activation of mTOR signaling occurred in bacterial induced colitis 
in mice, and made it crucial (146). mTOR inhibitors have shown to be effective as anti-
inflammatory drugs in colitis by inhibiting NF-B activation and T cell function (60, 62, 
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147). Targeted suppression of these activated pathways during colitis by natural 
compounds may provide an important strategy for preventing colitis. 
Polyphenolics are known to modulate the post-transcriptional regulation of 
miRNAs (71). The mTOR pathway is a promising target by miRNAs for anti-cancer 
therapeutics (68). miR-126 has target site in the promoter regions of phosphatidylinositol 
3-kinase regulatory subunit beta (PI3Kp85), an upstream component of the mTOR 
pathway (64, 69). Accordingly, miR-126 may be a potential chemopreventive and anti-
inflammatory target via the inhibition of angiogenesis, vascular integrity, inflammation, 
and proliferation (69). The induction of miR-126 could be a rationale for prevention and 
treatment of colitis.  
The objective of this study was to understand the molecular targets involved in 
anti-inflammatory effects of mango juice on dextran sodium sulfate (DSS)-induced 
colitis in Sprague Dawley rats and in lipopolysaccharide (LPS)-treated human CCD-
18Co colon-myofibroblastic cell lines. We hypothesized that mango juice has anti-
inflammatory properties in part due to the modulation of the miR-126/PI3K/AKT/mTOR 
pathway, which plays an important role in the inflammatory response in ulcerative 
colitis. In this study we are reporting for the first time that mango juice may modulate 
the post-transcriptional regulation of inflammation by regulate the expression of miR-
126.  
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Materials and methods 
Chemicals, antibodies, and reagents 
 DSS was purchased from MP biomedicals (Solon, OH). Antibody against Ki-67 
was purchased from BD Pharmingen (San Jose, CA). Antibodies against NF-B, pNF-
B, COX-2 were purchased from Cell signaling technology (Beverly, MA). The 
antibody for iNOS was purchased from Cayman chemical (Ann Arbor, MI). The 
antibodies for PI3K (p85 and HIF-1 were purchased from Abcam (Cambridge, MA). 
Lipofectamine 2000 was purchased from Invitrogen (Grand Island, NY). mirVana™ 
miRNA Isolation Kit, reverse transcription and real-time PCR amplification kits were 
purchased from Applied Biosciences (Foster City, CA). All primers were purchased 
from Integrated DNA Technologies (San Diego, CA). AntagomiR of miR-126 was 
purchased from Dharmacon (Lafayette, CO) (89).  
 
Mango chemistry 
 Mango (Keitt, Mexico) was received as a kind gift from the National Mango 
Board (Orlando, FL). For obtaining the experimental mango juice, full ripe mango was 
eled to remove skin and seed, and only the pulp was homogenized in a blender, and 
heated with cellulase and pectinase to break down the fiber. After heating at 55°C for 1h, 
the puree was centrifuged, and the supernatant was stored at -20°C. The mango extract 
for the in vitro study was prepared as described in our previous literature (81). Mango is 
a good source of dietary fiber (pectin and cellulose), vitamin C, ß-carotene, calcium, 
iron, and phenolic compounds (77). In this study, mango juice contained most of the 
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nutrients from fruit such as sugar, vitamin C, and polyphenolics except fiber, while 
mango extract had only total polyphenolics from mango. Total phenolic contents in the 
mango juice and extract were measured spectrophotometrically by the Folin-Ciocalteu 
assay against an external standard of gallic acid. Individual polyphenolics in the juice 
were analyzed on a Waters Alliance 2690 HPLC-MS system (Milford, MA). In addition, 
identification by mass spectrometric analyses was performed on a Thermo Finnigan 
LCQ Deca XP Max mass spectrometer equipped with an ESI ion source (Thermo Fisher, 
San Jose, CA) (81).  
 
Animal treatment and tissue sampling 
The animal use protocol was approved by the Institutional Animal Care and Use 
Committee of Texas A&M University. The DSS model is an excellent preclinical model 
of colitis that exhibits many phenotypic characteristics relevant to the human disease 
(148). The DSS treatment causes injury to the colonic epithelial barriers resulting in an 
increase in colonic mucosal permeability, causes destruction of the crypts, and produces 
pro-inflammatory cytokines (121). Ten week-old Sprague-Dawley rats supplied from 
Harlan Teklad (Houston, TX) were acclimated for a week, and were randomly 
distributed by weight into control and mango juice groups. For calorie and pH 
adjustment, 15.7g sugar and 0.05g citric acid was added in 100ml of control juice. The 
intake of liquid was determined every day. After 3 weeks of rat chow pellets and 
experimental juices ad libitum, all rats were administered 3% (w/v) DSS (3 cycles, 14 d 
separation, n=10/diet) in the experimental juices for 48 h. Rats were sacrificed 2 weeks 
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after three times of DSS administration, and colon tissues were collected (Figure 8). One 
centimeter sections were cut from the distal end of each rat colon, and fixed in 4% 
paraformaldehyde (PFA) for embedding in paraffin. The remained colon was gently 
scraped for collecting protein and RNA samples (149).  
 
 
Figure 8. Experimental design. 
 
Quantifying inflammation and cell proliferation assay 
For histopathology and immunohistochemistry analysis, colon tissues were 
dehydrated, embedded in paraffin and serially sectioned into 4 μm thick. Hematoxylin 
and eosin (H&E) stained slides were then examined by a board-certified pathologist 
(C.P.) in blinded manner for accessing the histological colitis level. Scores were assessed 
on a scale of 0-3, where 0 is none observed and 3 is severe inflammation (150). For Ki-
67 immunohistochemical staining, the primary antibody against Ki-67 (Dilution 1:50) 
was treated on the sections, and sections were incubated with biotinylated anti-mouse 
IgG from the Vectastain ABC Elite kit (Vector Lab, Burlingame, CA). Ki-67-containing 
nuclei, indicative of proliferating cells, showed up as brown spots within colonic crypt 
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columns. Twenty-five crypt columns per rat were selected for quantitative analysis. The 
number and position of labeled cells were recorded. Proliferative index was calculated as 
100 times the number of labeled cells divided by the total number of cells per crypt 
column.  
 
Cell culture 
Human colon CCD-18Co myofibroblastic cell lines were obtained from the 
American Type Culture Collection (ATCC; Manassas, VA), and cultured as 
recommended by the ATCC. Cells were seeded for cell proliferation assay onto a 24-
well plate (15,000 cells/well), for RNA extractions onto a 12-well plate (150, 000 
cells/well), and for the protein analysis onto a 6-well plates (300,000 cells/well). Cells 
were pre-incubated for 24h before exposing the treatment of the mango extract (0-10mg 
GAE/L). The level of cell viability was quantified with a cell counter after 48h (Z2TM 
Beckman coulter, Fullerton, CA). RNA was extracted for gene expression analysis after 
3h, and protein was extracted after 24h.  
 
Quantitative RT-PCR 
For mRNA and miRNA analysis, total and micro RNA from the colon mucosal 
scraping was isolated using the mirVana™ miRNA Isolation Kit according to the 
manufacturer’s protocol. Equal amount (1ug) of mRNAs was converted to cDNA using 
a reverse transcription kit (Invitrogen, Grand Island, NY). Real-time PCR reactions were 
performed using 2uL of cDNA using a Reverse Transcription Kit (Invitrogen, Grand 
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Island, NY). SYBR Green PCR master Mix (Applied biosystems, Foster City, CA) was 
used for the qPCR analyses on Applied Biosystems 7900HT Fast Real-Time PCR 
system (Applied biosystems, Foster City, CA). The sequence of primers was designed 
using Primer3, online primer design tool and were obtained from Integrated DNA 
Technologies (Coralville, IA). GAPDH was used as the endogenous loading control. 
Quantification of miR-126 was measured using the Taqman MicroRNA reverse 
Transcription kit (Applied Biosystems, Foster City, CA) and qRT-PCR reaction using 
Taqman 2X Universal PCR master mix (No AmpErase UNG) (Applied Biosystems, 
Foster City, CA). The miR-4.5S and miR-NU6B were used as endogenous control for 
micro RNA expression (89).  
 
Multiplex bead assay 
The protein extract (20ug) from each tissue was used to determine the relative 
abundance of total protein and the phosphorylation status in the AKT/mTOR signaling 
(AKT, mTOR, p70 S6 kinase, and RPS6) using the multiplex kits (Millipore, Billerica, 
MA) according to the manufacturer’s protocol. Multiplex analysis was performed by the 
Luminex L200 instrument (Luminex, Austin, TX), and data was analyzed by Luminex 
xPONENT software. 
 
Western blotting 
The mucosal scrapings were homogenized in protein buffer (500mM Tris-HCL, 
1M Sucrose, 200mM EDTA, 100mM EGTA, 0.4M NaF, 10% Triton X-100, 10mM 
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Sodium Orthovanadate, and Protease Inhibitor Cocktail), were centrifuged at 15,000 g 
for 20 min at 4°C, and the supernatant was stored in a -80°C freezer. After 24h mango 
extract treatment, cells were lysed in RIPA buffer added 1% protease and proteinase 
inhibitor cocktail (Pierce/Thermo Scientific, Rockford, IL), and centrifuged (151). 60ug 
of protein was loaded onto acrylamide gel, followed by transfer onto PVDF membranes. 
The membranes were incubated with primary antibodies against NF-B, p-NF-B, 
COX-2, iNOS, PI3K (p85, HIF-1 and -actin.  
 
Transfection with antagomiR of miR-126 
Cells seeded into 12-well plates were transfected with 20nM antagomiR of miR-
126 with using Lipofectamine 2000 according the manufacturer’s protocol. For the 
control, a nonspecific oligonucleotide was used. After transfection for 4h, the 
transfection mix was replaced with medium with 10mg GAE/L of mango extract, and 
after 1h, cells were treated with medium with mango extract and 1g/ml LPS for 24h as 
previously described (152). 
 
Statistical analysis 
Quantitative data represent mean values with standard error. Data were analyzed 
by student t-test and one way ANOVA using Tukey’s post hoc test (p<0.05) using SAS 
version 9 (SAS Institute Inc., Cary, NC).  
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Results  
Polyphenolics composition of mango juice and the juice consumption of DSS-treated 
rats 
The concentration of total soluble phenolics of mango juice used for this study 
was 475.80mg gallic acid equivalents (GAE)/L. HPLC-MS analysis of mango juice 
showed Monogalloyl Glucoside (Peak 1, 12.19mg GAE/L), Gallic acid (Peak 2, 6.41mg 
GAE/L), OH-Benzoic Acid hexoside (Peak 3, 2.97mg GAE/L), and Dihydrophaseic acid 
(Peak 4, 12.43mg GAE/L) with peak absorption at 280nm (Figure 9A). However, the 
overall the mango juice consumption and final body weight in the mango group were 
significantly lower compared to those in the control group (Table 3). The reason might 
be that it took time for rats to become used to the taste of tannins in the early stage of 
this study (Figure 9B). The total caloric intakes were not significantly different, because 
the food intake in the mango group was higher than the intake in the control group 
(Table 3). In addition, during the DSS administration, the intake of mango juice 
containing 3% DSS was significantly higher than the control juice, potentially due to the 
improvement of the bitter taste of DSS (Table 3). When a rat (445.39g body weight) 
drank 84.174ml of mango juice (475.80mg GAE/L), the dose was equivalent to 89.74 
mg GAE/kg/day in rats. The human equivalent amount of mango juice consumed by rats 
was calculated with the body surface area normalization method (human equivalent dose 
(mg/Kg)=rat dose (mg/Kg)×rat Km/human Km (6/37)) (153, 154). The 70 kg human 
equivalent dose of mango juice was around 1g GAE/day of mango polyphenolics or 
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2.1L/day of mango juice. There were no symptoms (for example, severe diarrhea or 
bloody stool) of severe inflammation after DSS treatment. 
 
 
 
Figure 9. Representative chromatographic profile at 280nm of phenolic compounds 
in mango juice (Keitt) and the daily liquid consumption by rats.  
(A) Total phenolic content of the mango juice was 475.80mg GAE/L. Tentative peak 
assignments: 1 Monogalloyl Glucoside (12.19mg GAE/L); 2 Gallic acid (6.41mg 
GAE/L); 3 OH-Benzoic Acid hexoside (2.97mg GAE/L); 4 Dihydrophaseic acid 
(12.43mg GAE/L). (B) The daily liquid consumption by rats was measured every day. 
Values are mean ± SEM (n=10 per group). 
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Table 3. Effects of mango juice on final body weight, food intake, juice intake, and 
caloric intake. 
Group Final Body 
weight (g) 
Food intake 
(g/day) 
Juice intake 
(ml/day) 
DSS containing 
Juice intake 
(ml/day) 
Caloric 
intake  
(kcal/day) 
Control 475.61 ± 7.18 8.725 ± 0.281 91.242 ± 0.993 38.667 ± 1.545  82.193 
Mango 445.39 ± 7.28* 10.888 ± 0.92* 84.174 ± 1.343* 42.333 ± 1.753* 84.713 
Each value is a mean ± SEM (n=10 per group). Values are statistically significant at 
*p<0.05. Food intake measured as the mean (± SEM) weight (g) of food intake per 48 
hour period at 8 weeks. Juice intake was calculated as the mean (± SEM) volume (ml) of 
juice consumed for whole study. Caloric intake was calculated on the basis of 3 kcal/g of 
pellet and 0.612 kcal/ml of juice. 
 
 
 
Mango reduced the inflammation score and decreased cell proliferation in DSS-treated 
rats 
The DSS-induced colitis murine model, which resembles human ulcerative 
colitis pathology, causes epithelial cell permeability and acute inflammation in colon. It 
is commonly used to test the efficacy of therapies such as food or drug on IBD (155). 
The 3 cycles of 3% DSS administration for 48h was sufficient to induce inflammation 
but not severe pathological ulceration (149, 154, 156). Histologic evaluation was done to 
access colonic inflammation injury. Mango juice intake reduced morphological signs of 
cell inflammation, and the inflammation score in the mango group was by 41% 
compared to the control juice (p=0.062, Figure 10A). Ki-67 proliferative index, an 
indicator for the level of cell proliferation, was primarily localized to the bottom and 
middle third of the crypts in both control and DSS groups (Figure 10B, C). The 
significant reduction in Ki-67 labeling in the mango juice group was detected compared 
to the control group (control 23.41% vs. mango 15.39%; P <0.05), which represented an 
8% reduction compared to the control group (Figure 10B). 
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Figure 10. Effects of mango juice on DSS-induced colonic inflammation (A) and 
colonocyte proliferation (B, C) in DSS-treated rats.  
Rats were fed a control juice or a mango juice, and were exposed to three cycles of DSS. 
(A) The inflammation score was decreased by the mango juice compared to the control 
juice intake in DSS-treated rats (p=0.062). Colonic inflammation was assessed by a 
board-certified pathologist (C.P.) in a blinded manner. Scores were assessed on a scale 
of 0-3. Values are mean ± SEM (n=10 per group). (B) Mango juice significantly 
suppressed colonocyte proliferation compared to control juice in DSS-treated rats. The 
measurement of Ki-67 was used to determine cell proliferation. Values are mean ± SEM 
(n=10 per group). *p < 0.05. (C) Ki-67 immunohistochemistry in rat colon mucosa in 
control and mango groups. 
 
 
 
Mango suppressed markers of inflammation in DSS-treated rats 
There is increasing evidence that gallic acid, a dominant polyphenolics in 
mango, targets key players in inflammation (141). Based on this information, we 
supposed that mango intake may reduce inflammation in colitis. To further quantify the 
effect of mango juice on inflammatory markers in vivo, we examined the inflammatory 
cytokines, NF-B, COX-2 and iNOS expression. Mango juice inhibits mucosal levels of 
the inflammatory cytokines TNF- and IL-1 mRNA (Figure 11A). The expression of 
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COX-2 and iNOS mRNA and NF-B p65, p- NF-B p65, COX-2 and iNOS protein 
expressions were reduced in DSS-treated rats consuming mango juice compared to the 
control group in colon epithelial cells (Figure 11B and C). 
 
 
 
Figure 11. Effects of mango juice on pro-inflammatory cytokines, NF-B, COX-2 
and iNOS in DSS-treated rats.  
Rats were fed a control juice or a mango juice, and were exposed to three cycles of DSS. 
Mango juice decreased the expressions of (A) TNF and IL-1 mRNA and (B) COX-2 
and iNOS mRNA in DSS-treated rats. Values are mean ± SEM (n=10 per group). 
*p<0.05. (C) Mango juice suppressed the expression of NF-B (p65), p-NF-B (p65), 
COX-2 and iNOS protein in DSS-treated rats.  
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Mango modulated the mTOR pathway and increased the expression of miR-126 in DSS-
treated rats 
The mammalian target of rapamycin (mTOR) pathway by activation of the 
PI3K/AKT pathway plays a central role in the regulation of cell growth, cell 
proliferation and inflammation through downstream transduction of proliferative signals, 
such as p70S6K, RPS6 and HIF-1(57). The suppression of the PI3K/AKT/mTOR 
pathway may represent a key role in the anti-inflammatory against colitis (60). Mango 
juice decreased the expression of PI3K, mTOR, p70S6K, and HIF-1 mRNA in DSS-
treated rats (Figure 12A). In addition, mango juice suppressed the expression of PI3K 
(p85) protein levels (Figure 12B) accompanied by decreased expression of AKT and 
mTOR total and phosphorylated protein, p70S6K phosphorylated protein, RPS6 total 
protein (Figure 12C and D), and HIF-1 protein levels in DSS-treated rats (Figure 12B). 
miRNAs may regulate the inflammatory response, and the mTOR pathway is a 
promising target by miRNAs (68). miR-126 is known to target PI3K (p85), which in 
turn regulates the PI3K/AKT signaling (64). Previously, we have shown that 
pomegranate polyphenolics reduced inflammation in AOM-treated rats via the 
modulation of the miR-126/PI3K pathway (152). Mango juice increased the expression 
of miR-126 compared to control juice (Figure 12E), which may be correspondingly 
accompanied by suppression of PI3K mRNA and protein expression in DSS-treated rats 
(Figure 12A and B).  
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Figure 12. Effects of mango juice on the mTOR signaling pathway in DSS-treated 
rats.  
Rats were fed a control juice or a mango juice, and were exposed to three cycles of DSS. 
(A) Mango juice decreased the expression of PI3K, mTOR, p70S6K1 and HIF-1 
mRNA in DSS-treated rats. (B) Mango juice suppressed the expression of PI3K (p85) 
and HIF-1 protein, (C) the total protein of AKT, mTOR and RPS6, and (D) the 
phosphorylated protein of AKT, mTOR and p70S6K1 in DSS-treated rats. (E) Mango 
juice increased the expression of miR-126 compared to control juice in DSS-treated rats. 
Values are mean ± SEM (n=10 per group). *p<0.05.  
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Mango decreased markers in the inflammatory and the mTOR signaling pathway in vitro 
Previously, we have shown the anticancer effects on mango extract in vitro, 
especially CCD-18Co cell lines (81). However, the specific mechanisms of the anti-
inflammatory effects of mango were unclear. Mango extract did not affect cell viability 
in CCD-18Co cells (Figure 13A). Similar results of in vivo study were obtained in vitro, 
LPS-treated CCD-18Co cell lines. Mango extract suppressed the expression of 
inflammatory markers, TNF- and IL-6 mRNA at 10mg GAE/L (Figure 13B), and the 
expression of NF-B, iNOS mRNA (Figure 13C) and NF-B, pNF-B protein (Figure 
13E) in LPS-treated CCD-18Co cells. In addition, mango extract also modulated the 
mTOR pathway in LPS-treated CCD-18Co cells. Mango extract suppressed the 
expression of PI3K (p85) and mTOR mRNA at 10mg GAE/L (Figure 13D), PI3K 
(p85) protein (Figure 13E), the total protein of p70S6K1 and RPS6 (Figure 13F), and 
the phosphorylated protein of mTOR and p70S6K1 (Figure 13G) in LPS-treated CCD-
18Co cells. Mango extract (0~10mg GAE/L) also increased the expression of miR-126 
in a dose-dependent manner in LPS-treated CCD-18Co cells (Figure 13H). 
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Figure 13. Effects of mango extract on the inflammatory and the mTOR signaling 
pathway in LPS-treated CCD-18Co cells.  
(A) Mango extract did not affect cell viability in CCD-18Co cells. (B) Mango extract 
suppressed the expression of inflammatory markers, TNF, IL-6, (C) NF-B, iNOS 
mRNA and the expression of in LPS-treated CCD-18Co cells. (D) Mango extract 
suppressed the expression of PI3K (p85) and mTOR mRNA in LPS-treated CCD-18Co 
cells. (E) Mango extract suppressed the expression of NF-B, pNF-B, PI3K (p85) and 
HIF1-proteins, (F) the total protein of p70S6K1 and RPS6, (G) the phosphorylated 
protein of mTOR and p70S6K1 in LPS treated CCD-18Co cells. (H) Mango extract 
increased the expression of miR-126 in LPS-treated CCD-18Co cells in dose dependent 
manners. Cells were treated different concentration of Mango extract (0-10 mg GAE/L) 
and LPS (1ug/ml) for 3h (RNA extraction) or 24h (Protein extraction). All experiments 
were performed at least three times, and result were expressed as mean ± SEM (n=3). 
Different letters indicate significance at p<0.05.  
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Figure 13 Continued.  
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The involvement of miR-126 in the mango-induced modulation of PI3K (p85) 
In order to determine the involvement of miR-126 and its target gene, PI3K 
(p85) in the anti-inflammatory activities of mango, we investigated the further in vitro 
treatment with antagomiR of miR-126. After the transfection of miR-126 antagomiR, 
cells were treated with the mango extract (10mg GAE/L) and 1g/ml LPS to induce 
inflammation. In results, the antigomiR treatment reduced the expression of miR-126, 
and mango extract partially reversed the effect of antagomiR-126 on transfected cells 
(Figure 14A). In addition, the reversed expression of miR-126 by mango treatment was 
accompanied by a decreased expression of PI3K (p85) mRNA (Figure 14B). It 
indicated that miR-126 has an important role in the modulation of PI3K signaling by 
mango treatment.  
 
Discussion 
Ulcerative colitis, the most common form of IBD, is a multi-factorial disorder, 
and the development of this disease is affected by several factors, such as genetic 
susceptibility, uncontrolled intestinal microbiota, immune dysregulation and 
environmental factors (5). Imbalance of the immune system causes the overproduction 
of reactive oxidative stress (ROS) and pro-inflammatory cytokines, such as IL-1β, IL-6, 
IL-8 and TNF- through NF-κB activation, and leads to chronic inflammation and 
mucosa damage in the large intestine (157). Although colitis is rarely lethal on its own, it 
is at high risk for developing colon cancer (40). Drugs have been mainly used for the 
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treatment of colitis, but natural compounds, in particular, polyphenols become as 
promising candidates due to their anti-inflammatory effects (50, 139).  
 
 
Figure 14. Effects of mango extract on miR-126 and PI3K mRNA levels in 
transfected CCD-18Co cells with a miR-126 antagomiR.  
CCD-18Co cells were transfected with 20nmol/ml of miR-126 antagomiR. After that, 
cells were treated with the mango extract (10mg GAE/L) and LPS (1ug/ml) for 24h. (A) 
Mango extract reversed the effect of miR-126 antagomiR on transfected cells. (B) The 
reversed expression of miR-126 was accompanied by a decreased expression of PI3K 
(p85) mRNA. miR-126 was analyzed as a ratio to the miR-NU6B endogenous control, 
and PI3K was assayed as ratio to GAPDH. All experiments were performed at least three 
times, and result were expressed as mean ± SEM (n=3). Different letters indicate 
significance at p<0.05. *p < 0.05. 
  
* * 
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Mango is a highly valued source of polyphenolics, such as gallic acid and 
gallotannins, which have been shown to have antioxidant, anti-inflammatory, and 
anticancer properties (140, 141, 143, 158). It has already shown that mango extracts play 
an anti-inflammatory role through reduction of inflammation related proteins such as 
iNOS, COX-2, and TNF- in murine colitis (84). However, the mechanisms underlying 
the anti-inflammatory activities of mango against colitis remains to be unclear. In this 
study, we demonstrated that mango intake reduced inflammatory response in colitis in 
vivo and in vitro through modulation of mTOR pathway and its post-translational 
modification.  
In this study, mango juice showed anti-inflammatory effects, as found in other 
studies (84). Mango intake slightly decreased the inflammatory scores (Figure 10A), and 
significantly suppressed cell proliferative index (Figure 10B) compared to control juice 
in DSS-treated rats. In the early process of colitis, LPS produced by bacteria and 
interferons (IFNs) by macrophage trigger signal transduction cascades, such as NF-B 
and mTOR pathways (56), that induce cell proliferation in colitis (159). The NF-B 
activation transcriptionally increases the expression of genes that encode pro-
inflammatory cytokines, IL-, IL-6, TNF-, COX-2 and iNOS in macrophages and 
epithelial cells (160). Induction of COX-2 and iNOS expression produce inflammatory 
mediators, such as free radical NO and PGE2 (161). Mango juice reduced the 
expressions of pro-inflammatory cytokines mRNA (TNF- and IL-1, Figure 11A), and 
inflammation-related markers NF-B protein, COX-2 and iNOS mRNA and proteins 
(Figure 11B, C) in the rat colitis model. In addition, mango extract also reduced the 
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expression of TNF- and IL-6 mRNA (Figure 13B), and NF-B mRNA and protein 
(Figure 13C and E) in LPS-treated in vitro model.  
The mammalian target of rapamycin (mTOR) pathway plays a central role in the 
regulation of cell proliferation and inflammation that lead to induce colitis (162). During 
colitis, LPS and IFN- stimulate PI3K/AKT signaling and mTOR pathway (56). 
Activation of mTOR leads to the activation of 4E-BP1 and p70S6K (57), that induce 
HIF-1 protein synthesis (163). The transcription factor HIF-1 regulates genes related 
to angiogenesis, cell growth, and proliferation (164). In DSS-induced colitis model, it 
was reported that induction of HIF-1 triggers inflammatory response by inducing pro-
inflammatory mediators (165). In a few studies, mTOR inhibitors have shown be 
effective to suppress DSS-induced colitis by inhibiting T cell function (60, 62). Targeted 
suppression of mTOR pathways during colitis by natural compounds may provide an 
important strategy for the prevention of colitis (166). In this study, mango suppressed the 
PI3K (p85) mRNA and protein (Figure 12A, B), and the total and phosphorylated 
expression of AKT and mTOR proteins in rat colitis model (Figure 12C, D). This result 
was consistent with in vitro studies where mango extract suppressed the PI3K (p85) 
mRNA and protein (Figure 13D, E), and the mRNA and phosphorylation of mTOR 
(Figure 13D, G). Downstream markers of mTOR pathway such as p70S6K, RPS6 and 
HIF-1 protein were also down regulated by mango intake compared to control juice 
(Figure 12B, C, and D).  
miRNAs modulate the inflammation due to the regulation of gene expressions 
by inducing mRNA degradation or blocking translation (167). The mTOR pathway is a 
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promising target by miRNAs for anti-colitis and anti-cancer therapeutics (68). miR-126 
has target site in the promoter region of phosphatidylinositol 3-kinase regulatory subunit 
beta (PI3Kp85), an upstream component of the mTOR pathway (64). Accordingly, 
miR-126 may be a potential anti-inflammatory target via the inhibition of angiogenesis, 
vascular integrity, inflammation, and proliferation (69). Our previous studies with red 
wine showed a significant suppression in inflammatory markers in LPS-treated CCD-
18Co cells, where also miR-126 was involved in the underlying mechanisms (168). In 
addition, we demonstrated that pomegranate polyphenolics decreased inflammation and 
reduce the PI3K/AKT pathways via modulation of miR-126 expression in AOM-treated 
rats and in colon cancer cell lines (152).  
In this study, mango decreased expression of PI3K (p85) mRNA and protein 
(Figure 12A, B and 13D, E) which was accompanied by up-regulation of miR-126 in 
vivo (Figure 12E) and in vitro (Figure 13H). PI3K (p85) is regulated by miR-126 
though a target-binding site in the 3’-UTR region of the PI3K (p85) mRNA (64). To 
confirm the relationship between miR-126 and PI3K (p85), cells were transfected to 
decrease the expression of miR-126 with the antagomiR for miR-126, whose 
concentration (20nM) were low enough to be overcome by the effects of mango. The 
effects of mango were significantly reversed the effect of inhibitor (Figure 14A), 
accompanied with the reduction of PI3K (p85) mRNA (Figure 14B).  
Certain limitations will require further experimentation in the future. The first 
limitation is that mango juice slightly but not significantly suppress the intestinal 
inflammation; however, several inflammatory markers were also evaluated in control 
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and mango juice group. In addition, the next approach can be to perform negative 
controls (control juice without DSS treatment) to compare the level of intestinal 
inflammation between the negative control and the mango juice group. A further 
limitation is that we did not use semi-purified diet but used rat chow pellets in this study. 
The chow diet typically contains soy protein, so it is not fully known all possible 
synergistic effects of mango polyphenolics and compounds in the soy protein, such as 
genistein, on the inflammation. In addition, colitis was induced in rats by DSS diluted in 
the experimental juice in this study. However, there can be a potential binding of DSS 
compounds on polyphenolics in the juice chemically, so DSS might not show the same 
toxicity in the control and mango juice group. Thus, investigating the detailed interaction 
among mango polyphenolics, soy proteins in the chow diet, and DSS compounds is 
essential for further understanding the effects of mango polyphenolics on colitis. 
Despite these limitations, our data from in vivo rat studies provide evidence of a 
causal role for mango juice in attenuating the level of inflammatory markers by 
suppressing the PI3K/AKT/mTOR signaling pathway in part though up-regulation of 
miRNA-126 expression. Interaction of mango with miR-126/PI3K/AKT/mTOR pathway 
was identified as the underlying mechanisms that is, at least in part, involved in the anti-
inflammatory of mango juice, and mango may be a potential therapeutic agent for colitis. 
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CHAPTER III  
POMEGRANATE POLYPHENOLICS REDUCE INFLAMMATION IN INTESTINAL 
COLITIS - POTENTIAL INVOLVEMENT OF THE MIR-145/P70S6K/HIF1-
PATHWAY IN VITRO AND IN VIVO 
 
Summary 
Pomegranate polyphenolics including ellagic acid, ellagitannins, flavonoids and 
anthocyanins, have previously been demonstrated effective in the prevention of 
inflammation. However, anti-inflammatory mechanisms relevant to the prevention of 
colitis have not been well investigated. 
This study investigates the potential role of the HIF1-signaling pathway in the 
anti-inflammatory effects of pomegranate juice on dextran sodium sulfate (DSS)-
induced colitis in Sprague Dawley rats and in human CCD-18Co colon-myofibroblastic 
cells. Animals were administered control juice (15.7g sugar and 0.05g citric acid/100ml) 
or pomegranate juice (total phenolic content of 2698.99mg/L GAE), and exposed to 
three cycles of 3% DSS. The a potential relationship between miR-145 and p70S6K1 
was elucidated by the treatment of 10mg GAE/L pomegranate extract and 1ug/ml LPS in 
transfected cell lines with a miR-145 antagomiR. The mRNA and protein levels were 
assessed in colonic mucosa by RT-PCR, western blotting and multiplex bead assay. 
Compared to the control, pomegranate suppressed cell proliferation (37.5%), and 
protected against DSS-induced colon inflammation and injury (50% and 66.7%). 
Pomegranate significantly down-regulated phosphorylation of p70S6K1, and decreased 
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HIF1-expression. p70S6K1 is the direct target of miR-145. Induction of miR-145 by 
pomegranate juice (2.0 fold) compared to control juice corresponds to the down-
regulation of p70S6K1. Pomegranate significantly attenuated the pro-inflammatory 
cytokines (TNF- and Il-1), COX-2 and iNOS. The involvement of miR-
145/p70S6K/HIF1was additionally investigated in CCD18Co, non-cancer colon 
fibroblasts, where the involvement of this pathway was confirmed using the specific 
antagomiR of miR-145, where the effects of pomegranate extract were in part reversed 
by the antagomiR.  
These results suggest that pomegranate intake attenuated DSS-induced colitis by 
modulating the miR-145/p70S6K/HIF1 pathway and inhibiting inflammatory 
responses, and it may be a potential therapeutic for colitis. 
 
Introduction 
Ulcerative colitis is a chronic and relapsing inflammation of the mucosal layer of 
the large intestine, such as the colon and rectum (43). Development of this disease is 
affected by multi-factorial conditions, such as genetic susceptibility, intestinal 
microbiota, immune dysregulation and environmental factors (e.g., smoking and diets 
high in fat and sugar) (3-5). A serious of long-term chronic inflammation causes loss of 
the lining of the colon, and produces high levels of pro-inflammatory cytokines and 
inflammatory molecules such as COX-2 and iNOS, which increases the risk of cancer. 
Accordingly, interventions that reduce intestinal inflammation may potentially reduce 
ulcerative colitis and related colon cancer risk. 
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Epidemiological and clinical studies suggested that polyphenolics derived from 
dietary sources are highly considered to be sources of natural antioxidant and the anti-
inflammatory properties by suppressing NF-B, COX-2 and iNOS activation (74, 75). 
The conventional therapeutics strategies reported a number of side effects, and thus, 
polyphenolics could contribute as complementary approaches to the management of 
colitis. Pomegranate is rich in polyphenols, including ellagic acid, ellagitannins, 
flavonoids and anthocyanins. It was shown that pomegranate and its polyphenolics exert 
antioxidant (169) and anti-inflammatory properties (170). Previously it was 
demonstrated that pomegranate extract reduced colitis severity via modulation of 
microbiota in guts (Bifidobacterium, Lactobacillus, and Clostridium) and decreasing 
COX-2, iNOS, PTGES, and PGE2 in DSS-induced colitis models (97). However, the 
underlying mechanisms relevant to reducing intestinal inflammation have not been well 
investigated. 
HIF1-is a heterodimeric nuclear transcription factor, and it plays an important 
regulator of epithelial barrier protection during colitis (171). On the other hand, during 
colitis, HIF1-expression was induced, and it was correlated with more severe colitis 
and increase in inflammatory infiltrates in colon. Furthermore, activation of HIF1-
increased expression of pro-inflammatory mediators (165). Targeted suppression of 
HIF1-during colitis by natural compounds may provide an important strategy for 
colitis and colon cancer prevention (166). The mechanism by which the expression of 
HIF1-can be regulated is unclear. The mTOR/p70S6K1 is one of potential regulator by 
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inducing the transduction of HIF1-and this pathway might be an important target for 
colitis treatment (57). 
miRNAs are a class of small non-coding RNA molecules that regulate mRNA 
degradation or repress their translation, and they are potential post-transcriptional 
regulators for the modulation of inflammatory and immune responses (63). miR-145 has 
target site in the promoter regions of p70S6K1, an downstream molecules of the mTOR 
pathway, and regulate the expression of HIF1-. miR-145 may be a potential anti-
inflammatory target for prevention and treatment of colitis and colon cancer. 
Furthermore, it was reported that dietary polyphenolics can be a potential post-
transcriptional regulator by modulating the expression of miRNAs (71). 
In this study, we investigated the molecular targets involved in anti-inflammatory 
activities of pomegranate juice on dextran sodium sulfate (DSS)-induced colitis in 
Sprague Dawley rats and in lipopolysaccharide (LPS)-treated human CCD-18Co colon-
myofibroblastic cells. We hypothesized that pomegranate polyphenolics has anti-
inflammatory activity in part due to the modulation of the miR-145/p70S6K1/HIF1-
pathway, which plays an important role in the inflammatory response in ulcerative 
colitis.  
  
Materials and methods 
Chemicals, antibodies, and reagents 
 DSS was purchased from MP biomedicals (Solon, OH). Antibody against Ki-67 
was purchased from BD Pharmingen (San Jose, CA). Antibodies against p70S6K1, 
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COX-2 were purchased from Cell signaling technology (Beverly, MA). The antibody for 
iNOS was purchased from Cayman chemical (Ann Arbor, MI). The antibody for HIF1-
was purchased from Abcam (Cambridge, MA). Lipofectamine 2000 was purchased 
from Invitrogen (Grand Island, NY). mirVana™ miRNA Isolation Kit, reverse 
transcription and real-time PCR amplification kits were purchased from Applied 
Biosciences (Foster City, CA). All primers were purchased from Integrated DNA 
Technologies (San Diego, CA). AntagomiR of miR-145 was purchased from from 
Dharmacon (Lafayette, CO).  
 
Pomegranate chemistry 
Pomegranate juice for the in vivo study was purchased from the POM wonderful 
(Los Angeles, CA). The pomegranate extract for the in vitro study was prepared as 
described in our previous literature (81). The pomegranate juice mainly contained sugar 
and polyphenolics, while pomegranate extract had only total polyphenolics from 
pomegranate. Total phenolic contents in the pomegranate juice and extract were 
measured spectrophotometrically by the Folin-Ciocalteu assay against an external 
standard of gallic acid. Individual pholyphenolics in the juice were analyzed on a Waters 
Alliance 2690 HPLC-MS system (Milford, MA). In addition, identification by mass 
spectrometric analyses were performed on a Thermo Finnigan LCQ Deca XP Max mass 
spectrometer equipped with an ESI ion source (Thermo Fisher, San Jose, CA) (81).  
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Animal treatment and tissue sampling 
The DSS-induced colitis model is the most effective in producing the clinical 
and histological features of UC characteristics in experimental animals (148). In 
particular, epithelial homeostasis, regeneration and wound healing in DSS-treated rats is 
similar to human IBD (127). Sprague-Dawley rats (10 week old) supplied from Harlan 
Teklad (Houston, TX) were acclimated for a week, and were randomly distributed into 
control juice and pomegranate juice groups. For calorie and pH adjustment, 15.7g sugar 
and 0.05g citric acid were added in 100ml of control juice. After 3 weeks of rat chow 
pellets and experimental juices ad libitum, all rats were administered 3% (w/v) DSS (3 
cycles, 14 d separation, n=10/diet) in the experimental juices for 48 h. Rats were 
sacrificed 2 weeks after three times of DSS administration, and colon tissues collected 
(Figure 15). One centimeter sections were cut from the distal end of each rat colon, and 
fixed in 4% paraformaldehyde (PFA) for embedding in paraffin. The remained colon 
was gently scraped for collecting protein and RNA samples (149). The animal use 
protocol was approved by the Institutional Animal Care and Use Committee of Texas 
A&M University. 
 
Figure 15. Experimental design. 
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Quantifying inflammation and cell proliferation assay 
For histopathology and immunohistochemistry analysis, colon tissues were 
dehydrated, embedded in paraffin and serially sectioned into 4 μm thick. Hematoxylin 
and eosin (H&E) stained slides were then examined by a board-certified pathologist 
(C.P.) in blinded manner for accessing the histological colitis level. The inflammation 
score was assessed on a scale of 0-3, where 0 is none observed and 3 is severe 
inflammation (150). The ulceration score was also assessed on a scale of 0-3; no damage 
was scored as 0 and several sites of ulceration or one large ulcer >1cm was scored as 3 
(172). For Ki-67 immunohistochemical staining, the primary antibody against Ki-67 
(Dilution 1:50) were treated on the sections, and sections were incubated with 
biotinylated anti-mouse IgG from the Vectastain ABC Elite kit (Vector Lab, 
Burlingame, CA). Twenty-five crypt columns per rat were selected for quantitative 
analysis. The number and position of labeled cells were recorded. Proliferative index 
was calculated as 100 times the number of labeled cells divided by the total number of 
cells per crypt column.  
 
Cell culture 
Human colon CCD-18Co myofibroblastic cells were obtained from the 
American Type Culture Collection (ATCC; Manassas, VA), and cultured as 
recommended by the ATCC. Cell were seeded for cell proliferation assay onto a 24-well 
plate (15,000 cells/well), for RNA extractions onto a 12-well plate (150, 000 cells/well), 
and for the protein analysis onto a 6-well plates (300,000 cells/well). Cells were pre-
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incubated for 24h before exposing the treatment of the pomegranate extract (0-10mg 
GAE/L). The level of cell viability was quantified with a cell counter after 48h (Z2TM 
Beckman coulter, Fullerton, CA). RNA was extracted for gene expression analysis after 
3h, and Protein was extracted after 24h.  
 
Quantitative RT-PCR 
For mRNA analysis, total and micro RNA from the colon mucosal scraping was 
isolated using the mirVana™ miRNA Isolation Kit according to the manufacturer’s 
protocol. Equal amount (1ug) of mRNAs was converted to cDNA using a reverse 
transcription kit (Invitrogen, Grand Island, NY). Real-time PCR reations were performed 
using 2uL of cDNA using a Reverse Transcription Kit (Invitrogen, Grand Island, NY). 
SYBR Green PCR master Mix (Applied biosystems, Foster City, CA) was used for the 
qPCR analyses on Applied Biosystems 7900HT Fast Real-Time PCR system (Applied 
biosystems, Foster City, CA). The sequence of primers were designed using Primer3, 
online primer design tool and were obtained from Integrated DNA Technologies 
(Coralville, IA). GAPDH was used as the endogenous loading control. Quantification if 
miR-145 was measured using the Taqman MicroRNA reverse Transcription kit (Applied 
Biosystems, Foster City, CA) and qRT-PCR reaction using Taqman 2X Universal PCR 
master mix (No AmpErase UNG) (Applied Biosystems, Foster City, CA). The miR-4.5S 
and miR-NU6B were used as endogenous control for micro RNA expression.  
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Multiplex bead assay 
The protein extract (20ug) from each tissue was used to determine the relative 
abundance of the total protein and phosphorylation status in the AKT/mTOR signaling 
(AKT, mTOR, p70S6 kinase, and RPS6) using the multiplex kits (Millipore, Billerica, 
MA) according to the manufacturer’s protocol. Multiplex analysis was performed by the 
Luminex L200 instrument (Luminex, Austin, TX), and data was analyzed by Luminex 
xPONENT software. 
 
Western blotting 
The mucosal scrapings were homogenized in protein buffer (500mM Tris-HCL, 
1M Sucrose, 200mM EDTA, 100mM EGTA, 0.4M NaF, 10% Triton X-100, 10mM 
Sodium Orthovanadate, and Protease Inhibitor Cocktail), were centrifuged at 15,000 g 
for 20 min at 4°C, and the supernatant was stored in a 80°C freezer. After 24h 
pomegranate extract treatment, cells were lysed in RIPA buffer added 1% protease and 
proteinase inhibitor cocktail (Pierce/Thermo Scientific, Rockford, IL), and centrifuged 
(151). 60ug of protein was loaded onto acrylamide gel, followed by transfer onto PVDF 
membranes. The membranes were incubated with primary antibodies against iNOS, 
COX-2, p70S6K1, HIF1-and -actin.  
 
Transfection with antagomiR of miR-145 
Cells seeded into 12-well plates were transfected with 20nM antagomiR of miR-
145 with using lipofectamin 2000 according the manufacturer’s protocol. For the 
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control, a nonspecific oligonucleotide was used. After transfection for 4h, the 
transfection mix was replaced with medium with 10mg GAE/L of pomegranate extract, 
and after 1h, cells were treated with medium with pomegranate extract and 1nM of LPS 
for 24h as previously described (151). 
 
Statistical analysis 
Quantitative data represent mean values with standard error. Data were analyzed 
by student t-test and one way ANOVA using Tukey’s post hoc test (p<0.05) using SAS 
version 9 (SAS Institute Inc., Cary, NC).  
 
Results  
Polyphenolic composition of pomegranate juice and the juice consumption of DSS-
treated rats 
The concentration of total soluble phenolics of pomegranate juice used for this 
study was 2698.99mg gallic acid equivalents (GAE)/L. HPLC-MS analysis of 
pomegranate juice showed the abundance of ellagintannins (Figure 16A), flavonoids 
(Figure 16B), and anthocyanins (Figure 16C). There was the most predominant 
ellagitannins, such as punicalins (peak 1), punicalagin (peak 2), ellagic acid glucoside 
(peak 3), and ellagic acid (peak 4) with peak absorption at 280nm (Figure 16A). 
However, the overall the pomegranate juice consumption and final body weight in the 
pomegranate group were significantly lower compared to those in the control group 
(Table 4). The reason might be that it took time for rats to become used to the taste of 
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tannins in the early stage of this study (Figure 16D). The total caloric intakes were not 
significantly different, because the food intake in the pomegranate group was increased 
(Table 4). In addition, during the DSS administration, the intake of pomegranate juice 
containing 3% DSS was significantly higher than the control juice, potentially due to the 
improvement of the bitter taste of DSS (Table 4). When a rat (440.41g body weight) 
drank 81.468ml of pomegranate juice (2698.99mg GAE/L), the dose was equivalent to 
499.27 mg GAE/kg/day in rats. The human equivalent amount of pomegranate juice 
consumed by rats was calculated with the body surface area normalization method 
(human equivalent dose (mg/Kg)=rat dose (mg/Kg)×rat Km/human Km(6/37)) (153, 154). 
The human equivalent dose of pomegranate juice was 5.6g GAE/day of polyphenolics or 
2L/day of pomegranate juice in 70kg human. There were no symptoms (for example, 
severe diarrhea or bloody stool) of severe inflammation after DSS treatment. 
 
Table 4. Effects of pomegranate juice on final body weight, food intake, juice 
intake, and caloric intake. 
Group Final Body 
weight (g) 
Food intake 
(g/day) 
Juice intake 
(ml/day) 
DSS containing 
Juice intake 
(ml/day) 
Caloric 
intake  
(kcal/day) 
Control 475.61 ± 7.18 8.725 ± 0.281 91.242 ± 0.993 38.667 ± 1.545  82.193 
Pomegranate 440.41 ± 5.57* 11.345 ± 0.64* 81.468 ± 2.042* 43.024 ± 1.378* 83.893 
Each value is a mean ± SEM (n=10 per group). Values are statistically significant at 
*p<0.05. Food intake measured as the mean (± SEM) weight (g) of food intake per 48 
hour period at 8 weeks. Juice intake was calculated as the mean (± SEM) volume (ml) of 
juice consumed for whole study. Caloric intake was calculated on the basis of 3 kcal/g of 
pellet and 0.612 kcal/ml of juice. 
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Figure 16. Representative chromatographic profiles at 280nm, 360nm and 520nm 
of phenolic compounds in pomegranate juice (POM wonderful) and the daily liquid 
consumption by rats.  
(A, B, and C) Total phenolic content of the pomegranate juice was 2698.99mg GAE/L. 
Tentative peak assignments: 1 Punicalins; 2 Punicalagins; 3 Ellagic acid glucoside; 4 
Ellagic acid; 5 Chlorogenic acid; 6 Quercetin-3-rutinoside; 7 Quercetin; 8 Flavonols; 9 
Cyanidin-3,5-diglucoside; 10 Delphinidin-3,5-diglucoside; 11 Delphinidin-3-glucoside; 
12 Cyanidin-3-glucoside. (D) The daily liquid consumption by rats was measured every 
day. Values are mean ± SEM (n=10 per group).  
 73 
 
Pomegranate reduced the inflammation and ulceration scores and suppressed cell 
proliferation in DSS-treated rats 
The DSS-induced colitis model is the most effective in producing the clinical 
and histological features of ulcerative colitis characteristics in experimental animals. 
This model is a valuable tool for investigating the involvement of dietary factors into in 
pathogenesis of IBD and evaluating different therapeutic options (128). The 3 cycles of 
3% DSS administration for 48h was sufficient to induce inflammation but not severe 
pathological ulceration (149, 154, 156). Histologic evaluation was done to access 
colonic inflammation and ulceration. Pomegranate juice slightly reduced the 
inflammation score, and significantly decreased ulceration scores by 50% and 66.7% 
compared to the control juice (p=0.059 and <0.05, Figure 17A, B). The significant 
reduction in Ki-67 labeling in the pomegranate group was detected compared to the 
control group (37.5% reduction; P <0.05) (Figure 17C, D).  
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Figure 17. Effects of pomegranate juice on DSS-induced colonic inflammation and 
ulceration (A) and colonocyte proliferation (B) in DSS-treated rats.  
Rats were fed a control juice or a pomegranate juice, and were exposed to three cycles of 
DSS. (A) The inflammation score was slightly decreased, and the ulceration score was 
significantly decreased by the pomegranate juice compared to the control juice intake in 
DSS-treated rats (p=0.059). Colonic inflammation and ulceration was assessed by a 
board-certified pathologist (C.P.) in a blinded manner. Scores were assessed on a scale 
of 0-3. Values are mean ± SEM (n=10 per group). (B) Pomegranate juice significantly 
suppressed colonocyte proliferation compared to control juice in DSS-treated rats. The 
measurement of Ki-67 was used to determine cell proliferation. Values are mean ± SEM 
(n=10 per group). *p < 0.05.  
 
Pomegranate suppressed markers of inflammation 
There is increasing evidence that ellagic acid, a dominant juice in pomegranate, 
targets key players in inflammation (93, 94). Based on this information, we supposed 
that pomegranate intake may suppress inflammation. To further quantify the effect of 
pomegranate juice on inflammatory markers in vivo, we examined the inflammatory 
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cytokines, iNOS and COX-2 expression. Pomegranate juice inhibits mucosal levels of 
the inflammatory cytokines TNF-and IL-1 mRNA (Figure 18A). The expression of 
iNOS and COX-2 mRNA and protein levels were reduced in DSS-treated rats 
consuming pomegranate compared to the control group in colon epithelial cells (Figure 
18A and B). 
 
 
           
 
Figure 18. Effects of pomegranate juice on pro-inflammatory cytokines, COX-2 
and iNOS in DSS-treated rats.  
Rats were fed a control juice or a pomegranate juice, and were exposed to three cycles of 
DSS. Pomegranate juice decreased the expressions of (A) TNF, IL-1, COX-2 and 
iNOS mRNA in DSS-treated rats. Values are mean ± SEM (n=10 per group). *p<0.05. 
(B) Pomegranate juice suppressed the expression of iNOS and COX-2 protein in DSS-
treated rats.  
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Pomegranate modulated the p70S6K1 expression and increased the expression of miR-
145 in DSS-treated rats 
The HIF-1plays a central role in the regulation of cell growth, cell 
proliferation and inflammation in colitis. Activation of the mTOR/p70S6K1 promotes 
cell growth and cell proliferation via downstream transduction of proliferative signals, 
such as HIF-1(57). The suppression of the HIF1-may represent a key role in the 
anti-inflammatory against colitis (165). Pomegranate juice decreased the expression of 
mTOR, p70S6K, and HIF1-mRNA in DSS-treated rats (Figure 19A). In addition, 
pomegranate juice suppressed the expression of p70S6K total protein and 
phosphorylated protein, RPS6 phosphorylated protein (Figure 19B and C), and HIF1-
protein levels in DSS-treated rats (Figure 19D). miR-145 is known to target p70S6K1, 
which in turn regulates the HIF1-(70). We have already shown that pomegranate juice 
suppressed inflammation in AOM-treated rats via the induction of miR-126 expression 
(152). However, in this study, pomegranate juice increased the expression of miR-145 
compared to control juice (Figure 19E), which may be correspondingly accompanied by 
suppression of p70S6K1 mRNA and protein expression in DSS-treated rats (Figure 19A, 
B and C).  
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Figure 19. Effects of pomegranate juice on the mTOR signaling pathway in DSS-
treated rats. 
Rats were fed a control juice or a pomegranate juice, and were exposed to three cycles of 
DSS. (A) Pomegranate juice decreased the expression of mTOR, p70S6K1 and HIF1- 
mRNA in DSS-treated rats. (B) Pomegranate juice suppressed the total protein of 
p70S6K1, (C) the phosphorylated protein of p70S6K1 and RPS6, (D) the expression of 
HIF1-protein in DSS-treated rats. (E) Pomegranate juice increased the expression of 
miR-145 compared to control juice in DSS-treated rats. Values are mean ± SEM (n=10 
per group). *p<0.05. 
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Pomegranate decreased the markers in the inflammatory and the mTOR signaling 
pathway in vitro 
Previously, we have shown the anticancer effects on pomegranate juice in the 
breast and colon cancer models (89, 152). However, the specific mechanisms of the anti-
inflammatory effects of pomegranate in colitis were not elucidated. Pomegranate extract 
did not affect cell viability in CCD-18 cells (Figure 20A). Similar results of in vivo study 
were obtained in LPS treated CCD-18Co cell lines. Pomegranate extract suppressed the 
expression of inflammatory marker, iNOS mRNA at 10mg GAE/L in LPS-treated CCD-
18 cells (Figure 20B). In addition, pomegranate extract also modulated the 
mTOR/p70S6K1/HIF1-in LPS-treated CCD-18 cells. Pomegranate extract suppressed 
the expression of mTOR, p70S6K1 and HIF1-mRNA at 10mg GAE/L (Figure 20C), 
and p70S6K1 and HIF1-protein expression (Figure 20D) in LPS-treated CCD-18Co 
cells. Pomegranate extract (0~10mg GAE/L) also increased the expression of miR-145 
in a dose-dependent manner in LPS-treated CCD-18 cells (Figure 20E). 
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Figure 20. Effects of pomegranate extract on the inflammatory and the HIF1-
signaling pathway in LPS-treated CCD-18 cells. 
 (A) Pomegranate extract did not affect cell viability in CCD-18 cells. (B) Pomegranate 
extract suppressed the expression of inflammatory markers, iNOS mRNA in LPS-treated 
CCD-18 cells. (C) Pomegranate extract suppressed the expression of mTOR, p70S6K1, 
and HIF1-mRNA, and the expression of p70S6K1 and HIF1-proteins in LPS treated 
CCD-18 cells. (E) Pomegranate extract increased the expression of miR-145 in LPS-
treated CCD-18 cells. Cells were treated different concentration of pomegranate extract 
(0-10 mg GAE/L) and LPS (1ug/ml) for 3h (RNA extraction) or 24h (Protein 
extraction). All experiments were performed at least three times, and result were 
expressed as mean ± SEM (n=3). Different letters indicate significance at p<0.05.  
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The involvement of miR-145 in the Pomegranate-induced modulation of p70S6K1 
In order to determine the involvement of miR-145 and its target gene, p70S6K1 
in the anti-inflammatory activities of pomegranate, we investigated the further in vitro 
treatment with antagomiR of miR-145. After the transfection of miR-145 antagomiR, 
cells were treated with the pomegranate extract and LPS to induce inflammation. In 
results, pomegranate extract partially reversed the effect of miR-145 antagomiR on 
transfected cells (Figure 21A). The reversed expression of miR-145 was accompanied by 
a decreased expression of p70S6K1 mRNA (Figure 21B) and protein (Figure 21C). It 
indicated that miR-145 has an important role in the modulation of p70S6K1 signaling by 
pomegranate treatment.  
 
Discussion 
Pomegranate polyphenolics is a highly valued, functional food that has 
antioxidant and anti-inflammatory activities in vivo and in vitro (169, 170). It was 
already reported that pomegranate and its polyphenolics play an anti-inflammatory role 
in colitis. Ellagic acid inhibited NF-B activity through induction of IkB 
phosphorylation and suppression of reduced IL-8 secretion in Caco-2 (93), and reduced 
colitis severity via reduction of MPO and TBARS activity in DSS-treated rats (94). 
Dietary pomegranate showed the anti-inflammatory properties through inhibition of 
MPO activity and TNF levels in chronic TNBS-induced colitis. In addition, 
pomegranate decreased COX-2 and iNOS expression, and reduced MAPK pathway 
(p38MAPK, JNK, and ERK1/2) and NF-B activities in the TNBS-treated rats (95, 96). 
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In DSS-induced colitis models, pomegranate extract reduced colitis severity via 
modulation of microbiota in guts (Bifidobacterium, Lactobacillus, and Clostridium) and 
decreasing COX-2, iNOS, PTGES, and PGE2 (97).  
 
 
 
Figure 21. Effects of pomegranate extract on miR-145 and p70S6K1 mRNA levels 
in in LPS-treated CCD-18 cells.  
CCD-18Co myofibroblast colon cells were transfected with 20nmol/ml of miR-145 
antagomiR. After that, cells were treated with the pomegranate extract (10mg GAE/L) 
and LPS (1ug/ml) for 24h. (A) Pomegranate extract reversed the effect of miR-145 
antagomiR on transfected cells. The reversed expression of miR-145 was accompanied 
by a decreased expression of (B) p70S6K1 mRNA and (C) protein. miR-145 was 
analyzed as a ratio to the miR-NU6B endogenous control, and p70S6K1 was assayed as 
ratio to GAPDH. All experiments were performed at least three times, and result were 
expressed as mean ± SEM (n=3). Different letters indicate significance at p<0.05. *p < 
0.05. 
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These anti-inflammatory properties of pomegranate may help protect against 
human cancer. In the human lung carcinoma cells and lung tumors in mice, pomegranate 
polyphenols down-regulated inflammation by suppressing PI3K/AKT pathway and 
decreased the activation of NF-B. In addition, pomegranate extracts have shown to 
induce cytotoxicity and anti-inflammatory properties in colon cancer in vitro and in vivo 
by inhibiting PI3K/AKT pathway and the activation of NF-B (102). However, the 
mechanisms underlying the anti-inflammatory activities of pomegranate against colitis is 
unclear. The objective of the present study is to understand the anti-inflammatory effects 
of pomegranate polyphenolics on colitis in vivo and in vitro through modulation of 
HIF1-pathway and its post-translational modification. 
Ulcerative colitis is the most common form of IBD, characterized by a chronic 
and relapsing inflammation of the mucosal layer of the colon. Although colitis is rarely 
lethal on its own, it is at high risk for developing colon cancer (40). DSS-induced colitis 
is a well-established model whose symptoms and colonic histopathology are 
phenotypically similar to human colitis (155). This model is characterized by high levels 
of nitric oxide produced by the induction of iNOS expression during the inflammation 
status. Our results showed that pomegranate juice suppressed iNOS induction caused by 
DSS treatment. In this study, pomegranate juice intake slightly decreased the 
inflammatory score, and significantly decreased the ulceration score (Figure 17A) and 
cell proliferative index (Figure 17C) compared to control juice in DSS-treated rats. 
Moreover, pomegranate juice suppressed the expressions of pro-inflammatory cytokines 
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(TNF-, IL-1), and inflammation-related proteins COX-2 and iNOS (Figure 18A, B, 
and 20B) in the rat colitis model and in LPS treated in vitro model.  
HIF1-plays a central role in the regulation of angiogenesis, cell proliferation 
and inflammation that lead to induce colitis (165). During colitis, HIF1-expression 
was induced, and it was correlated with more severe colitis and increase in inflammatory 
infiltrates in colon. Furthermore, activation of HIF1-increased expression of pro-
inflammatory mediators (165), and it was known that the target genes of the 
transcription factor HIF-1 are VEGF, HO-1, iNOS (173) and COX2 (174). HIF-1 
inhibitors have shown be effective to suppress DSS-induced colitis by inhibiting pro-
inflammatory cytokines (165). The mTOR/p70S6K1 is an important signaling pathway 
in the regulation of inflammation via downstream transduction of HIF1-(57). Targeted 
suppression of the mTOR/p70S6K1/HIF1-during colitis by natural compounds may 
provide an important strategy for colitis (166).  
In previous studies, pomegranate polyphenols have been shown to anti-
inflammatory properties in lung and colon cancer by suppressing the PI3K/AKT 
pathway and decreasing the activation of NF-B (98, 100-102). Based on these studies, 
we hypothesized that the inhibition of the PI3K/AKT pathway by pomegranate juice 
may modulate the expression of mTOR and determined whether the inhibition of 
inflammatory pathway by pomegranate was due in part by suppressing the mTOR 
pathway. In the results, pomegranate suppressed the pro-inflammatory cytokines, iNOS 
and COX expression. This finding agrees with previous findings where it was 
demonstrated that pomegranate juice decreased inflammation and suppress the COX-2 
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and iNOS in DSS-induced colitis models (97). In addition, pomegranate juice reduced 
the expression of the p70S6K1 mRNA and protein (Figure 19A, B, C), and HIF-1 
proteins in rat colitis model (Figure 19D), and this was consistent with in vitro studies 
where pomegranate extract suppressed the p70S6K1 mRNA and protein, and the HIF-1 
(Figure 20C, D). 
microRNAs are emerging as a potential link between inflammation and cancer 
due to the modulation of gene expressions by inducing mRNA degradation or blocking 
translation (63). The HIF-1 is a promising target by miRNAs (175). miR-145 is an 
colon cancer suppressor genes, and plays an important role in regulating colon cell fate 
(176). It was reported that miR-145 is an important regulator in the innate immune 
system, and loss of miR-145 increased colitis (177, 178). Our previous studies with 
pomegranate showed the anti-cancer properties in breast and colon cancers through 
miRNAs modulations. In this study, pomegranate increased expression of p70S6K1 
which was accompanied by up-regulation of miR-145 in vivo (Figure 19E) and in vitro 
(Figure 20E). p70S6K1 is regulated by miR-145 though a target-binding site in the 3’-
UTR region of the p70S6K1 mRNA . To confirm the relationship between miR-145 and 
p70S6K1, cells were transfected with the antagomiR for miR-145 to slightly reduce the 
expression of miR-145, where the effects of pomegranate were slightly reversed the 
effect of inhibitor (Figure 21A), accompanied with the suppression of p70S6K1 mRNA 
and protein (Figure 21B, C). The concentration of antagomiR (20nM) were low enough 
to be overcome by the effects of pomegranate. This indicates that miR-145 is involved in 
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the pomegranate-induced down-regulation of HIF-1 and may modulate inflammation 
and proliferation.  
In conclusion, pomegranate juice attenuated DSS-induced colitis by suppressing 
the p70S6K1/HIF-1 signaling pathway in part though up-regulation of miRNA-145 
expression. Interaction of pomegranate with miR-145/ p70S6K1/HIF-1 pathway was 
identified as the underlying mechanisms that is, at least in part, involved in the anti-
inflammatory of pomegranate juice, and pomegranate may be a potential therapeutic 
agent for colitis. 
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CHAPTER IV 
COMPARISON OF ANTI-INFLAMMATORY MECHANISMS OF MANGO 
(MANGIFERA INDICA L.) AND POMEGRANATE (PUNICA GRANATUM L.) IN 
DSS-INDUCED COLITIS 
 
Summary 
Polyphenolics from mango (gallic acid, galloyl derivatives, flavonol glycosides 
and benzophenone derivatives), and pomegranate (ellagic acid, ellagitannins, flavonoids, 
and anthocyanins) have been shown to have potent antioxidant and anti-inflammatory 
properties. Ulcerative colitis, a chronic inflammation of the large intestine, may increase 
risk of human colorectal cancer. Polyphenolics have been shown to suppress 
inflammation through different mechanisms, including inhibition of the mTOR signaling 
pathway. 
To determine the anti-inflammatory effects and possible mechanisms of mango 
and pomegranate juice in DSS-induced colitis in rats, Sprague Dawley (SD) rats were 
administered control juice (15.7g sugar and 0.05g citric acid/100ml), mango juice (Total 
phenolic content of 475.80mg/L GAE), or pomegranate juice (Total phenolic content of 
2698.99mg/L GAE), and were exposed to three cycles of 3% dextran sodium sulfate 
(DSS) in the drinking juice followed by 2-week recovery period. Colon inflammation 
and ulceration scores were assessed. The levels of protein involved in the AKT/mTOR 
pathway were analyzed by multiplex bead assay, while the transcriptional variation with 
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the mTOR pathway were analyzed by low density PCR arrays. In addition, the levels of 
several miRNAs involved in the mTOR pathway were measured.  
Both mango and pomegranate juice reduced DSS-induced colon inflammation 
during chronic colitis in rats compared to control juice. Mango juice suppressed the IGF-
1R-AKT/mTOR signaling axis via up-regulation of miR-126 and down-regulation of IR, 
while pomegranate decreased p70S6K by up-regulating miR-145 and down-regulation of 
the MEK-ERK1/2 pathway.   
These results suggest that polyphenolics of different predominant structure may 
differentially regulate inflammation-involved pathways while attenuating DSS-induced 
colitis. For the further study, there may be possible synergistic interactions between both 
polyphenolics classes in the reduction of inflammation. 
 
Introduction 
Ulcerative colitis (UC) is a chronic relapsing inflammatory condition in the 
colon. Active immune cells destroy the intestinal barrier through releasing reactive 
oxygen species (ROS), and pro-inflammatory cytokines (2). 1.4 million people in the 
United States and 2.2 million people in Europe suffer from these diseases (3). The most 
serious complications of UC is high risk of developing human colorectal cancer (40). 
The risk of colorectal cancer increased with duration of the disease with a cancer risk of 
2% by 10 years, 8% by 20 years and 18% by 30 years, and it has high mortality (> 50%) 
(41, 42). Therefore, it is important to identify the mechanisms underlying suppression of 
the intestinal inflammation.  
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The mTOR pathway may play a key role during ulcerative colitis (60-62). Once 
PI3K is activated by insulin, IGF-1, or TLR4, it starts a signal transduction cascade via 
the AKT/mTOR pathway. mTOR exists in two complexes within the cell: mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Activation of mTORC1 
regulates protein synthesis (HIF1), cell growth, and cell proliferation via downstream 
transduction of proliferative signals, such as 4E-BP1 and p70S6K (57). The transcription 
factor HIF-1 has target genes, such as VEGF, HO-1, iNOS (173) and COX2 (174). This 
pathway is a promising target of miRNAs for anti-colitis and anti-cancer therapeutics 
(68). Targeted suppression of these activated pathways during colitis using natural 
compounds provides an important strategy for colitis and colon cancer prevention. 
Mango is rich in polyphenols, such as gallic acid and gallotannins. It was 
reported that mango extract has anti-inflammatory properties via reduction of iNOS, 
COX-2, TNF and TNFR-2 in a DSS-induced model of colitis (84). Pomegranate is 
rich in ellagic acid, ellagitannins, flavonoids, and anthocyanins. Pomegranate showed 
the anti-inflammatory properties through suppression of COX-2 and iNOS expression, 
MAPK pathway (p38MAPK, JNK, and ERK1/2), and NF-B activities in chemically-
induced colitis (95, 96). However, the mechanisms underlying anti-inflammatory 
activities of polyphenolics is unclear yet.  
It was reported that different classes of polyphenolics may have different anti-
inflammatory activities, possibly due to the structural variations or the different cellular 
targets (179). In the above described studies with DSS-induced colitis, we were shown 
that mango and pomegranate juice differently modulated the mTOR pathway. The 
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results suggest that juice of different structure may differentially regulate inflammation-
involved pathways while attenuating DSS-induced colitis. 
Proteomic and gene expression analysis allows us to figure out the potential 
therapeutic target in prevention of inflammatory disease and to elucidate the underlying 
mechanisms how the polyphenolics ameliorate the inflammatory response (180). In 
addition, we can compare the gene expression changes altered by different polyphenolics 
intake in vivo models for investigating the mechanisms underlying the anti-
inflammatory activities. Therefore, in this study, we determined how mango and 
pomegranate juice influence colonic inflammation, proteomics and mucosal gene 
expression involved in the mTOR pathway. In addition, we have compared the 
underlying mechanisms altered by mango and pomegranate juice.   
 
Materials and methods 
Fruit preparation 
Mango (Keitt, Mexico) was homogenized and centrifuged for obtaining the 
experimental mango juice. After that, the supernatant was stored at -20°C to prevent 
oxidation. Pomegranate was purchased from the POM wonderful (Los Angeles, CA). 
The concentration of total polyphenolics were mango juice (475.90mg GAE/L) and 
pomegranate juice (2698.99mg GAE/L). The control juice was adjusted its calorie and 
pH to Brix 15.7 and pH 3.4 (Table 5). 
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Table 5. The nutritional analysis for the experimental juices. 
 Control juice Mango juice Pomegranate juice 
Brix 15.7 15.6 15.8 
pH 3.4 3.3 3.5 
Total polyphenolics (mg GAE/L)  475.90 2698.99 
Vitamin C (mg/L)  6.13 10.17 
 
Animal treatment and tissue sampling 
DSS-induced colitis is an excellent preclinical model of colitis that exhibits many 
phenotypic characteristics such as epithelial homeostasis, regeneration and wound 
healing, relevant to the human disease (127, 148). This model is a valuable tool for 
investigating involvement of dietary factors into the pathogenesis of IBD and evaluate 
different therapeutic options (128). Ten week-old Sprague-Dawley rats obtained from 
Harlan Teklad (Houston, TX) were acclimated for a week and randomly grouped (n=10) 
by weight into control, mango and pomegranate juice groups. After 3 weeks of rat chow 
pellets and experimental juices ad libitum, all rats were administered 3% (w/v) DSS (MP 
Biomedicals, Solon, OH) (3 cycles, 14 d separation, n=10/diet) in the experimental 
juices for 48 h. Rats were sacrificed 2 weeks after three times of DSS administration, 
and the entire colon was removed. One centimeter sections were cut from the distal end 
of each rat colon, and fixed in 4% paraformaldehyde (PFA) for embedding in paraffin. 
The remained colon was gently scraped for collecting protein and RNA samples (149). 
The animal use protocol was approved by the Institutional Animal Care and Use 
Committee of Texas A&M University. 
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Histological scoring 
For histopathology analysis, sections were stained with hematoxylin and eosin 
(H&E). Slides were examined by a board-certified pathologist (C.P.) in blinded manner 
for accessing the degree of inflammation (score, 0-3) and ulceration (score, 0-3) (150). 
The presence of rare inflammatory cells in the lamina propria was scored as 0; increased 
number of inflammatory cells was scored as 1; predominant inflammatory cells as 2; and 
the inflammatory infiltrate as 3 (181). For the evaluation of ulceration, no damage was 
scored as 0; One linear ulcer <1cm length was scored as 1; Two linear ulcer <1cm length 
was scored as 2; More sites of ulceration or one large ulcer >1cm was scored as 3 (172).  
 
Multiplex bead assay 
The protein extract (20ug) from each tissue was used to determine the relative 
abundance of the phosphorylation status and total protein in the mTOR signaling (Akt, 
GSK3β, GSK3α, IGF1R, IR, IRS1, mTOR, p70 S6 kinase, PTEN, RPS6, and TSC2) 
using the multiplex kits (Millipore, Billerica, MA) according to the manufacturer’s 
protocol. Multiplex analysis was performed by the Luminex L200 instrument (Luminex, 
Austin, TX), and data was analyzed by Luminex xPONENT software. 
 
miRNAs analysis 
miRNAs were isolated from scraped mucosa using the mirVana™ miRNA 
Isolation Kit (Applied Biosciences, Foster City, CA) by following the manufacturer’s 
protocol. Quantifications of miRNAs relevant to the mTOR pathway, such as Let7a, 
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miR-21, miR-126, miR-143, miR-145, and miR-155, were measured using the Taqman 
MicroRNA reverse Transcription kit (Applied Biosystems, Foster City, CA). The miR-
4.5S was used as endogenous control for microRNAs expression (89). 
 
Low density PCR array (mTOR and MAPK pathways) 
mRNA (400ng) was converted to cDNA by using a RT2 First-strand cDNA 
synthesis kit (Qiagen, Valencia, CA). RT-PCR for mTOR and MAPK pathways were 
performed by using RT2-Profiler PCR array (n=5/group; Qiagen, Valencia, CA) by using 
ABI 7900HT PCR system (Applied biosystems, Foster City, CA). The low density PCR 
array takes advantages of SYBR Green-based RT-PCR and microarray. Each plate 
contains gene specific primer sets for 84 relevant pathway genes. Analysis of the results 
was performed by the zRMicroArray. Only genes that passed the significance test 
(p<0.05) were considered. 
 
Statistical analysis 
Data were expressed as means with their standard errors. Data were analyzed by 
one way ANOVA using Tukey’s post hoc test (p<0.05) using SAS version 9 (SAS 
Institute Inc., Cary, NC) or ANOVA R-package with is embedded in zRMicroArray. P 
values <0.05 were accepted as significant.  
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Results  
Pomegranate but not mango juice protected against intestinal ulceration in DSS treated 
rats 
To explore the effects of mango and pomegranate juice on DSS-induced colitis, 
rats were treated with three cycles of 3% DSS for 48h, and colonic inflammation and 
ulceration were assessed. Inflammation and ulceration scores represent the degree of 
immune cell infiltration and ulceration, respectively. Mango and pomegranate juice 
slightly decrease colonic inflammation scores (p=0.062 and 0.059). With respect to the 
ulceration score, the pomegranate juice significantly decreased ulceration score (p<0.05) 
compared with control (Figure 22). This data suggest that mango and pomegranate may 
affect the pathology of DSS-induced colitis by modulating immune cell infiltration. In 
addition, pomegranate juice showed more protective effects compared to mango juice.  
 
 
 94 
 
 
Figure 22. Effects of mango and pomegranate juice on DSS-induced colonic 
inflammation and ulceration in rats.   
Rats were fed a control, mango, or pomegranate juice, and were exposed to three cycles 
of DSS. The inflammation scores were slightly decreased by the experimental juice 
intake compared to the control juice intake (p=0.062 and 0.059). The ulceration scores 
were significantly reduced by pomegranate juice. Colonic inflammation and ulceration 
was assessed by a board-certified pathologist (C.P.) in a blinded manner. Scores were 
assessed on a scale of 0-3. Values are mean ± SEM. Different letters indicate significant 
differences among groups (n=10; p<0.05).  
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Modification of the mTOR signaling pathway by juice  
The mTOR pathway may play an important role in colitis (60-62). The pathway 
is activated by hormones, mitogens and growth factors, and the activation may regulate 
protein synthesis, cell growth, and cell proliferation (57). Mango juice decreased the 
expression of IGF1R, AKT, TSC2, mTOR, and RPS6 total protein, and the expression of 
IR, IGF1R, PTEN, AKT, GSK3, TSC2, mTOR, and p70S6K phosphorylated protein. 
Meanwhile, pomegranate juice decreased the expression of p70S6K total protein, and the 
expression of GSK3, p70S6K, and RPS6 phosphorylated protein (Figure 23).  
 
 
 
Figure 23. Proteomic profiling altered by mango and pomegranate juice in DSS 
treated rats.  
Rats were fed a control, mango, or pomegranate juice, and were exposed to three cycles 
of DSS. The intensity of the green color indicated the degree of down-regulation (green, 
low abundance; white, not significant; n=10 per group; p<0.05). 
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MicroRNAs targeting the mTOR pathway were altered by mango and pomegranate juice  
miRNAs are potential post-transcriptional regulators for the regulation of 
inflammatory and immune responses (63). The mTOR pathway is a promising target of 
miRNAs for anti-colitis and anti-cancer therapeutics (68). Moreover, polyphenolics are 
known to modulate post-transcriptional regulation by regulating the expression of 
miRNAs (71). Mango juice significantly increased the expression of Let7a, miR-126, 
and miR-143, while pomegranate juice decreased the expression of miR-126 and miR-
143 compared to the levels of the control group. In addition, pomegranate increased the 
miR-145 levels (Figure 24). miR-126 targets PI3Kp85β, an upstream component of the 
mTOR pathway (64), and miR-145 targets p70S6K1, a downstream target of the mTOR 
pathway (70). Increased miR-126 and miR-145 by juice could provide a rationale for the 
suppression of the mTOR pathway.  
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Figure 24. miRNAs expression altered by mango and pomegranate juice in DSS 
treated rats.  
Rats were fed a control, mango, or pomegranate juice, and were exposed to three cycles 
of DSS. Mango juice increased the expression of Let7a, miR-126, and miR-143, and 
pomegranate juice decreased the expression of miR-126, miR143, and increased miR-
145 compared to control juice in DSS treated rats. A green–red gradient represents 
abundance differences (green, low abundance; red, high abundance; white, not 
significant; n=10 per group; p<0.05). 
 
  
 98 
 
Mango and pomegranate modulate mucosal gene expression involved in the mTOR 
pathway 
Gene expression analysis of mTOR pathway was determined by comparing the 
juice groups with control group. The mTOR pathway alteration by mango and 
pomegranate juice were compared in order to elucidate the different effects of different 
polyphenolics contributing the anti-inflammation. Among 84 genes involved in the 
mTOR pathway, each six genes had a significant differential expression by mango and 
pomegranate juice (p<0.05). Of these, Pld1, Ppp2r2b, and Tp53 genes were overlapped. 
The expression of Ppp2r2b and Tp53 were up-regulated, while Pld1 expression was 
down-regulated by mango and pomegranate juice. The gene expression of Igf1, Insr, and 
Pik3cd genes were down-regulated by mango juice, and Rps6ka2, Rragd, and Vegfc 
were differentially expressed by pomegranate juice (Table 6 and Figure 25).  
 
Table 6. Differentially expressed genes in the mTOR pathway by mango and 
pomegranate juice. 
Symbol Gene name GenebankID Relative 
expression 
p-value Relative 
expression 
p-value 
  Mango Pomegranate 
Ppp2r2b Protein phosphatase 2 (formerly 2A), 
regulatory subunit B, beta isoform 
NM_022209 2.993 0.026 2.792 0.037 
Tp53 Tumor protein p53 NM_030989 2.585 0.045 2.367 0.049 
Pld1 Phospholipase D1 NM_030992 0.342 0.049 0.350 0.044 
Igf1 Insulin-like growth factor 1 NM_178866 0.573 0.038   
Pik3cv Phosphoinositide-3-kinase, catalytic, beta 
polypeptide 
NM_053481 0.351 0.045   
Insr Insulin receptor NM_017071 0.608 0.047   
Vegfc Vascular endothelial growth factor C NM_053653   0.428 0.007 
Rps6ka2 Ribosomal protein S6 kinase polypeptide 
2 
NM_057128   0.455 0.035 
Rragd Ras-related GTP binding D NM_001106641   2.241 0.040 
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Figure 25. Differentially expressed genes involved in the mTOR signaling altered 
by mango or pomegranate juice.  
Venn diagram categorized the differentially expressed gene sets. A green–red gradient 
represents abundance differences (green, low abundance; red, high abundance; white, 
not significant; n=5 per group; p<0.05). 
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Mango and pomegranate modulate mucosal gene expression involved in the MAPK 
pathway 
The MAPK pathway is an important regulator of the mTOR pathway. The 
MAPK pathway was reported to promote mTORC1 activity independently of the 
PI3K/AKT pathway (182). Gene expression analysis of the MAPK pathway was also 
determined by comparing the juice groups with control group. Among 84 genes involved 
in the MAPK pathway, seven and eight genes had a significant differential expression by 
mango and pomegranate juice, respectively (p<0.05). Of these, Ccne1, Map3k2, Pak1, 
and Tp53 genes were overlapped. The expression of Ccne1, Map3k2, and Pak1 were up-
regulated, while Tp53 expression was up-regulated by mango and pomegranate juice. 
The gene expression of Mapk9, Mapk10, and Rac1 genes were down-regulated by 
mango juice, while Cdc42, Map2k2, Mapk1, and sfn were down-regulated by 
pomegranate juice (Table 7 and Figure 26).  
 
Table 7. Differentially expressed genes in the MAPK pathway by mango and 
pomegranate juice. 
Symbol Gene name GenebankID Relative 
expression 
p-value Relative 
expression 
p-value 
  Mango Pomegranate 
Ccne1 Cyclin E1 M_00110082 0.460 0.022 0.532 0.023 
Pak1 P21 protein (Cdc42/Rac)-activated kinase 1 NM_017198 0.456 0.042 0.480 0.044 
Tp53 Tumor protein p53 NM_030989 3.991 0.045 3.093 0.026 
Map3k2 Mitogen activated protein kinase kinase kinase 
2 
NM_138503 0.570 0.047 0.639 0.032 
Rac1 Ras-related C3 botulinum toxin substrate 1 NM_134366 0.489 0.017   
Mapk10 Mitogen activated protein kinase 10 NM_012806 0.445 0.036   
Mapk9 Mitogen-activated protein kinase 9 NM_017322 0.564 0.049   
Map2k2 Mitogen activated protein kinase kinase 2 NM_133283   0.495 0.027 
Cdc42 Cell division cycle 42 (GTP binding protein) NM_171994   0.499 0.030 
Mapk1 Mitogen activated protein kinase 1 NM_053842   0.432 0.036 
Sfn Stratifin XM_232745   0.443 0.037 
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Figure 26. Differentially expressed genes involved in the MAPK pathway altered by 
mango or pomegranate juice.  
Venn diagram categorized the differentially expressed gene sets. A green–red gradient 
represents abundance differences (green, low abundance; red, high abundance; white, 
not significant; n=5 per group p<0.05). 
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Confirmatory analysis of proteomic and gene expression analysis 
To define an appropriate measure of similarity for gene expression patterns and 
total and phosphorylated protein levels, it was verified the results from the low density 
array with multiplex total and phosphorylated protein assay. In the correlation between 
total protein and mRNA and phosphorylated protein and mRNA, the R2 values were 
R2=0.5956 and R2=0.0906 respectively (Figure 27). 
 
   
Figure 27. Correlation analysis of total or phosphorylated protein abundance and 
mRNA expression.  
Data are expressed as the ratio of the experimental juice groups relative to the control 
group (R2=0.5956 and 0.0906). 
 
 
Discussion 
Dietary mango and pomegranate polyphenolics have received substantial 
attention for their antioxidant and anti-inflammatory effects (84, 95, 96). In this study, 
we compared the anti-inflammatory properties of two bioactive compounds on 
experimental colitis in rats. Ulcerative colitis, the most common form of IBD, is 
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characterized by a chronic and relapsing inflammation of the mucosal layer of the large 
intestine, which includes the colon and rectum (5). It was shown that different classes of 
flavonoids may have different effects on inflammation at mRNA and protein level, 
possibly due to substantial structural differences (179) . In the above described studies 
with DSS-induced colitis, mango and pomegranate polyphenolics differently modulated 
the anti-inflammatory mechanisms. The results suggest that polyphenolics of different 
structure may differentially regulate inflammation-involved pathways while attenuating 
DSS-induced colitis. In this comparative study, we compared the mechanisms altered by 
mango and pomegranate juice involved in modulation of the mTOR pathway using 
proteomic and gene expression analysis. 
Results demonstrate that both mango and pomegranate juice slightly decreased 
colonic inflammation scores, where only pomegranate juice significantly decreased the 
ulceration score compared to the control juice. This may be based on two reasons, a) 
difference in juice concentrations (475.90 and 2698.99mg GAE/L) and b) difference in 
predominant juice structure (gallotannins and ellagitanins). 
The mTOR pathway plays an important role in colitis (60, 62, 147). Suppression 
of the mTOR pathways during colitis using natural compounds may provide an 
important strategy in the prevention of colitis. Our data show that mango juice decreased 
the up and downstream components of the mTOR pathway in the colonic mucosa, while 
pomegranate juice only decreased the downstream targets of the mTOR pathway (Figure 
23, 25 and Table 6) even though the concentration of pomegranate juice was higher. In 
addition, the insulin/IGF-1 signaling pathway might be the main target of mango juice. 
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The insulin/IGF-1 receptor activates a number of signaling transduction pathway, 
including the PI3K/AKT pathway during colitis (183). Mango juice may suppress the 
insulin receptor, and modulate dependent intracellular signaling pathways and gene 
expression.  
Polyphenolics are known to modulate post-transcriptional regulation by 
regulating the expression of miRNAs (71). The mTOR pathway is an important target of 
miRNAs in anti-colitis and anti-cancer therapeutics (68). Mango juice may suppress the 
AKT/mTOR signaling via up-regulation of miR-126 and Let7a, while pomegranate 
decreased p70S6K by up-regulating miR-145 (Figure 24). 
Initially, we hypothesized that pomegranate juice may suppress inflammation at 
least in part through down-regulation of the mTOR pathway as mango juice did. 
However, the hypothesis was only partially acceptable (Figure 23, 25). In this study, 
pomegranate juice did not affect the activators of the mTOR pathway, however 
decreased the down-stream modulators of mTOR-regulated kinases involved in cell 
proliferation and inflammation. For this reason, alternative pathways involved in the 
regulation of mTOR-dependent kinases such as the MAPK pathway were investigated 
using gene expression. Previously, dietary pomegranate showed anti-inflammatory 
activities through inhibition of MAPK pathway (p38MAPK, JNK, and ERK1/2) in 
chronic TNBS-induced colitis (95, 96). Like the PI3K/AKT axis, the MAPK pathway is 
also a key modulator of mTOR pathway. Results indicate that low density arrays 
relevant to the MAPK pathway revealed that pomegranate juice may down-regulate the 
gene expressions involved in the MEK-ERK1/2 signaling compared to the control group 
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(Figure 26). ERK1/2 is a regulator of p70S6K (184), and the suppression of ERK1/2 by 
pomegranate juice may contribute to the down-regulation of p70S6K. Results also show 
that both, mango and pomegranate juice down-regulated Cyclin E1 and up-regulation of 
P53 and that this may contribute to their anti-inflammatory functions (Figure 26).  
When performing correlation-analysis between proteomic and gene expression 
analysis, the correlation between total protein and mRNA and phosphorylated protein 
and mRNA were R2=0.5956 and R2=0.0906 respectively. This may indicate that juice 
reduce inflammation mainly at the level of post-transcriptional modification. Gene 
expression analysis is a fast and cheap large-scale sequencing compared to proteomic 
assay. However, although gene expression analysis provides a critical information 
addressing the anti-inflammatory mechanisms of botanical compounds, proteomic assay 
may be more relevant to biological functions due to post-transcriptional modification 
(185). 
In conclusion, data show that mango and pomegranate juice differentially 
modulate the mTOR pathway in DSS-induced colitis in rats. Mango juice appear to 
inhibit the entire IGF-1-PI3K/AKT-mTOR axis, while pomegranate juice regulate the 
downstream of the mTOR pathway through the reduction of ERK1/2. Results indicate 
further that there may be possible synergistic interactions between both juice classes in 
the reduction of inflammation.  
. 
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CHAPTER V  
MANGO AND POMEGRANATE POLYPHENOLICS IN THE MODIFICATION OF 
MICROBIOTA AND SHORT CHAIN FATTY ACIDS IN DSS-INDUCED COLITIS 
 
Summary 
Dysregulation of the interactions between gut microbiota and the immune system 
seems to be involved in triggering inflammation. Gut microbiota can be modulated by 
dietary compounds such as fiber and polyphenolics. To evaluate the effects of mango 
and pomegranate polyphenolics on fecal microbiota and short chain fatty acid (SCFAs) 
production, Sprague Dawley (SD) rats were administered control, mango, or 
pomegranate juice, and were exposed to three cycles of 3% dextran sodium sulfate 
(DSS) in the drinking juice followed by 2-week recovery period. Pro-inflammatory 
cytokines were analyzed in serum and mucosal samples. Fecal samples were collected 
one week before the end of the study to characterize the fecal microbiota composition 
using selected representative genus by qPCR and to measure SCFAs concentration. The 
mRNA levels involved in host energy metabolisms were assessed in colonic mucosa by 
RT-PCR.  
Mango and pomegranate juice decreased the level of pro-inflammatory 
cytokines, such as IL-1b and GM-CSF in serum, and induced the level of IL-10. 
Pomegranate juice induced compositional changes in the fecal microbiota. In particular, 
the anti-inflammatory Ruminococcaceae significantly was increased by pomegranate 
juice in the feces but the concentrations of SCFAs were not significantly affected. In 
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response to the mango juice, fecal SCFAs isovalerate and valerate were increased, while 
there was no significant change in the composition of the intestinal microbiota at the 
genus level. Polyphenolics decreased the expression of the TLR4 receptor that is 
triggered by lipopolysaccharide expressed in the membrane of gram negative bacteria, 
and mango juice also increased the GPR43 receptor which is a receptor for SCFAs. In 
addition, among the genes related energy metabolism and autophagy, autophagy marker 
Light chain 3 (lc3) and Lactate dehydrogenase A (ldha) that convert pyruvate to lactate 
was up-regulated while Monocarboxylate transporter 4 (slc16a3), which is lactate and 
butyrate transporter, was down-regulated by mango and pomegranate juice. In summary, 
mango juice induced changes in the SCFAs production while pomegranate juice induced 
changes in the composition of microbiota associated with the SCFAs production, 
however pomegranate did not alter the concentrations of SCFAs themselves.   
 
Introduction 
Ulcerative colitis (UC) is a kind of inflammatory bowel disease (IBD), which is 
characterized by chronic inflammation of the colonic mucosa. The development of this 
disease is affected by four factors: genetic susceptibility, intestinal microbiota, immune 
dysregulation, and environmental factors (e.g., smoking and diets high in fat and sugar) 
(3-5). The microbiota are integral in triggering and enhancing inflammation. For 
example, germfree IL-10 gene deficient mice had no evidence of intestinal inflammation 
or colitis (12). 
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There are more than 1014 microbiota, from more than 1000 species, in the 
gastrointestinal tract, mostly in the colon. Microbiota activate the immune system to 
produce reactive oxidative stress (ROS) or cytokines, and they are involved in the 
development of inflammatory disease and colon cancer. Gram-negative bacteria 
(Bacteroides, Fusobacterium, and Escherichia coli) containing lipopolysaccharide (LPS) 
partly though the induction of the toll-like receptors (TLR)s/MyD88/NF-κB signaling 
pathway (18) and overproduction of pro‐inflammatory cytokines, such as TNF- and IL-
6 (19, 20). Bifidobacterium and Lactobacillus are considered to be probiotics that induce 
health benefits, and exert anti-inflammatory properties through inhibition of NF‐κB 
activation and IL‐8 secretion (21). Other gram-positive bacteria (Ruminococcaceae, 
Blautia, Faecalibacterium, and Streptococcus) were also shown to have anti-
inflammatory effects, as the production of SCFAs blocked NF-κB activation and the 
induction of IL-10 (22).  
SCFAs are a sub-group of fatty acids with 2 to 6 carbons, primarily acetate, 
propionate, butyrate, and valeric acid (23). SCFAs are metabolites produced from 
undigested carbohydrates, fibers, proteins and polyphenols by protective microbiota, and 
they seem to be beneficial in the suppression of inflammatory responses and UC (24). 
SCFAs, especially butyrate bind the G-protein coupled receptor 43 (GPR43) or GRP41 
(FFAR3), and suppress inflammatory responses, as it decreases the production of pro-
inflammatory cytokines (IL-1β, TNF-α, IL-12, IL-17, inducible protein (IP)-10), 
increases the production of anti-inflammatory cytokine IL-10, and suppresses the 
activation of various immune cells such as macrophages, eosinophil, T cells, B cells, and 
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dendritic cells (24, 26). SCFAs might play a key role in the prevention and treatment of 
colitis.  
Most polyphenolics pass from the small intestine to the colon, which indicates 
the importance of the colon in polyphenolics. Hydrolyzable tannins such as Gallotannins 
and ellagitannins are hydrolyzed by gut microbiota and then can be absorbed in the 
colon (186). It has been reported that polyphenolics and their metabolites influence the 
composition and function of the gut microbiota (107). The metabolism of the gut 
microbiota on polyphenolics may modify the immune response and the potential health 
effects. 
Previously, it was shown that mango and pomegranate extracts had anti-
inflammatory properties in DSS-induced colitis model (84, 97). However, the specific 
mechanisms is unclear. Mango is rich in polyphenols, including gallic acid and 
gallotannin. Increased levels of Clostridium and Bacteroides are a cause of colitis, and 
the growth of athogenic E. coli and Clostridium perfringens was strongly inhibited by 
gallic acid (110). Gallotannins showed anti-microbiota activity against most gram-
positive bacteria except E. coli, Pseudomonas, and lactic acid (111). Pomegranate is rich 
in ellagic acid and ellagitannins. It was reported that pomegranate extract reduced colitis 
severity via modulation of the microbiota in the gut (Bifidobacterium, Lactobacillus, and 
Clostridium) in DSS-induced colitis models (97).  
Based on this information, the objective of this study was to understand the 
interactions between the fecal microbiota and mango and pomegranate juice on DSS-
induced colitis in Sprague Dawley rats. We hypothesized that mango and pomegranate 
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juice may mitigate inflammation in DSS-induced colitis model in part by altering 
microbiota composition and SCFAs production. In addition, we have investigated the 
underlying mechanisms relevant to the prevention of colitis by the SCFAs production. 
 
Materials and methods 
Fruit preparation 
Mango (Keitt, Mexico) was received as a kind gift from the National Mango 
Board (Orlando, FL). For obtaining the experimental mango juice, full ripe mango was 
peeled to remove skin and seed, and only the pulp was homogenized in a blender, and 
heated with cellulase and pectinase to break down the fiber. After heating at 55°C for 1h, 
the puree was centrifuged, and the supernatant was stored at -20°C to prevent oxidation. 
Pomegranate was purchased from the POM wonderful (Los Angeles, CA). The 
concentration of total polyphenolics were mango juice (475.90mg GAE/L) and 
pomegranate juice (2698.99mg GAE/L). The sugar concentrations of juices were 15.6 
and 15.8%, and the pH was 3.3 and 3.5, respectively. The control juice was adjusted its 
calorie and pH to Brix 15.7 and pH 3.4. 
 
Animal treatment and tissue sampling 
DSS-induced model of colitis is an excellent preclinical model of colitis that 
exhibits many phenotypic characteristics such as epithelial homeostasis, regeneration 
and wound healing, relevant to the human disease (127, 148). This model is a valuable 
tool for investigating the relationship between intestinal inflammation and microbiota 
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composition (114). Ten week-old Sprague-Dawley rats were obtained from Harlan 
Teklad (Houston, TX) and were acclimated for a week. After that, they were randomly 
grouped (n=10) by weight into control, mango and pomegranate juice groups. After 3 
weeks of rat chow pellets and experimental juices ad libitum, all rats were administered 
3% (w/v) DSS (MP Biomedicals, Solon, OH) (3 cycles, 14 d separation, n=10/diet) in 
the experimental juices for 48 h. Fresh fecal and serum samples were collected one week 
before the end of the study. Blood was collected from sublingual vein under anesthesia. 
At 10 weeks, rats were sacrificed and the entire colon was removed. The colon was 
gently scraped for collecting RNA samples (149). The animal use protocol was approved 
by the Institutional Animal Care and Use Committee of Texas A&M University. 
 
Multiplex bead assay 
The serum and mucosal tissue samples were used to determine the levels of 
inflammatory marker, C-reactive protein (CRP) and the cytokines (TNF, IL-1, GM-
CSF, IFN, IL-6 and IL-10) using the multiplex kits (Millipore, Billerica, MA) 
according to the manufacturer’s protocol. Multiplex analysis was performed by the 
Luminex L200 instrument (Luminex, Austin, TX), and data was analyzed by Luminex 
xPONENT software. 
 
Quantitative real-time PCR assays 
qPCR targeting 16S rRNA genes is a useful tool for quantifying very low 
concentrations of bacterial targets in fecal samples. Bacterial DNA was extracted from 
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fecal samples using a bead-beating phenol-chloroform method as previously described. 
Further steps of DNA extraction and puriﬁcation were performed using a commercial 
DNA extraction kit (Qiagen) according to the manufacturer's instructions (187). qPCR 
assays for selected bacterial groups were performed: total bacteria, Bacteroidetes, 
Fusobacteria, Blautia, Ruminococcaceae, Faecalibacterium spp., Turicibacter spp., 
Bifidobacterium spp., E coli, Lactobacillus, and Streptococcus. The qPCR data was 
expressed as log amount of DNA (fg) for each particular bacterial group per 10 ng of 
isolated total DNA (188). 
 
SCFA analysis 
SCFA analysis was performed using a gas chromatograph (HP 5890, Hewlett-
Packard, Palo Alto, CA, USA) coupled to a quadrupole mass spectrometer (HP-5989A). 
Sample preparation for short chain fatty acids with GC/MS assay is as follows. Grinded 
feces (0.5g) were vortexed in 2N HCL for 30 minutes followed by centrifugation at 
3000rpm for 20 min. The upper phase was transferred to C18 cartridge after adding 
200mM internal standard (d7-butyric acid). The sample was then eluted with diethyl 
ether. Removing top layer was repeated after adding diethyl ether and vortexing for 
15min. After adding MTBSTFA(N-tert-butyldimethylsilyl-N ethytrifluoracetamide), 
samples was transferred to vials for the GC/MS injection. Dry matter weights of fecal 
samples were used to normalize the concentration of SCFAs.  
 
  
 113 
 
Quantitative RT-PCR 
For mRNA analysis related energy metabolism and autophagy, total RNA from 
the colon mucosal scraping was isolated using the mirVana™ miRNA Isolation Kit 
(Applied Biosciences, Foster City, CA ) according to the manufacturer’s protocol. Equal 
amount (1ug) of mRNAs was converted to cDNA using a reverse transcription kit 
(Invitrogen, Grand Island, NY). Real-time PCR reactions were performed using 2uL of 
cDNA using a Reverse Transcription Kit (Invitrogen, Grand Island, NY). SYBR Green 
PCR master Mix (Applied biosystems, Foster City, CA) was used for the qPCR analyses 
on Applied Biosystems 7900HT Fast Real-Time PCR system (Applied biosystems, 
Foster City, CA). The sequence of primers was designed using Primer3, online primer 
design tool and were obtained from Integrated DNA Technologies (Coralville, IA). 
GAPDH was used as the endogenous loading control.  
 
Statistical analysis 
Quantitative data represent mean values with standard error. Data were analyzed 
by student t-test and one way ANOVA using Tukey’s post hoc test (p<0.05) using SAS 
version 9 (SAS Institute Inc., Cary, NC). Differences in the proportions of microbiota 
between groups were analyzed using a non-parametric Kruskal-Wallis test with Dunn’s 
multiple comparison test afterwards to compare individual groups (Prisms5, GraphPad 
Software Inc.). p<0.05 was considered for statistical significance.   
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Results  
Mango and pomegranate juice decreased pro-inflammatory cytokines 
 C-reactive protein (CRP) binds to phosphocholine expressed on the surface of 
dead cells, and it is used as a marker of inflammation (189). In this study, we measured 
the concentration of CRP and pro-inflammatory cytokine levels in serum and mucosal 
samples. Serum levels of IL-1 and GM-CSF were decreased in the mango and 
pomegranate groups compared to the control group (Figure 28A). In addition, the level 
of CRP and pro-inflammatory cytokines such as TNF, IL1, GM-CSF, and IL-6 in 
mucosal sample were lower in the juice group than the control group (Figure 28B).  
 
Modification of the intestinal microbiota 
An aberrant ratio of microbiota in the large intestine can be integral in triggering 
and enhancing IBD. Polyphenolics and their metabolites can influence the composition 
and function of the gut microbiota (107). Feces samples were collected from rats at 9 
weeks to investigate the changes in the gut microbiota by qPCR. At the genus level, 
pomegranate juice resulted in fecal abundance of Blautia, Fusobacterium, and 
Ruminococcaceae ratio compared to the control group (p<0.05). Interestingly, mango 
juice resulted in an increase of Bacteroidetes and Lactobacillus as well as a reduction of 
Fusobacterium, and Ruminococcaceae ratio in feces microbiota compared to the 
pomegranate group (Figure 29).  
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(A)      
 
(B) 
 
Figure 28. Effects of mango and pomegranate juice on CRP and pro-inflammatory 
cytokines in serum and DSS-induced colitis. 
Rats were fed a control juice or a mango juice, and were exposed to three cycles of DSS. 
(A) Serum CRP and cytokine levels, (B) CRP and cytokines in colonic tissue. Values are 
mean ± SEM. Different letters indicate significant differences among groups (n = 10; 
p<0.05). 
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Figure 29. The influence of mango and pomegranate juice on microbiota. 
Heatmap represents the relative log2 ratio of each sample. A green–red gradient 
represents abundance differences (green, low abundance; red, high abundance; black, not 
significant).The “V” under the picture denote significant differences in relative 
proportions observed between each groups (based upon Kruskal-Wallis test; p<0.05).  
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Modification of SCFAs production 
SCFAs are produced by the anaerobic microbiota, therefore the change of 
microbiota composition may alter the SCFAs production. The major SCFAs is acetate 
(60%), propionate (25%), and butyrate (15%) (24). Mango juice resulted in an increase 
of isovalerate and valerate compared to the control group, as well as an increase of 
propionate compared to the pomegranate group (p<0.05) (Figure 30).  
 
 
Figure 30. SCFAs production by mango and pomegranate juice  
Values are mean ± SEM. Different letters indicate significant differences among groups 
(n = 10; Kruskal-Wallis test; p<0.05). 
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Mango and pomegranate juice modulate the expressions of TLR4and GPR43 
The TLR4/MyD88 receptor responses LPS contained gram-negative bacteria 
(Bacteroides, Fusobacterium, and Escherichia coli), and causes inflammation through 
the induction of NF-κB signaling pathway (18) and overproduction of pro‐inflammatory 
cytokines, such as TNF- and IL-6 (19, 20). GPR41 and GPR43 are SCFA receptor, 
which are involved in the anti-inflammatory mechanisms, lipid and glucose metabolism 
(190). To determine the interaction between colonocytes, microbiota and SCFAs, we 
screened the gene expressions involved in the receptors, which ligand to the microbiota 
and SCFAs. Both mango and pomegranate juice decreased the level of TLR4 mRNA, 
while mango induced the expression of GRP43 mRNA (Figure 31).  
 
 
 
Figure 31. The level of TLR4, MyD88, GRP43, and GRP41 mRNA altered by 
mango and pomegranate juice.  
Values are mean ± SEM. Different letters indicate significant differences among groups 
(n = 10; p<0.05). 
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Mango and pomegranate juice altered gene expressions involved in the energy 
metabolism and autophagy 
SCFAs exert beneficial effects on host energy metabolism, because colonocytes 
prefer to derive their energy supply from SCFAs oxidation (191). The interaction of 
GRP receptors and SCFAs seem to affect glucose metabolism in colonocytes (191), and 
autophagy can be partially modulated the glucose metabolisms altered by SCFAs (192). 
We investigated the effect of juice on lactate metabolism and autophagy associated 
genes to explain the relationship between SCFAs modulation by juice and energy 
metabolism. Mango and pomegranate juice dramatically modulated an increase of 
LDHA as well as a decrease of MCT4 (Figure 32A), which are involved in the lactate 
metabolism where LDHA converts pyruvate to lactate and MCT4 is lactate and butyrate 
transporter. Among genes involved in the autophagy pathway, LC3, a representative 
marker of autophagosomes, were up-regulated by juice (Figure 32B). 
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(A)                                                             (B) 
 
 
 
 
 
 
Figure 32. Gene expressions related to lactate metabolism and autophagy altered 
by mango and pomegranate juice.  
Values are mean ± SEM. Different letters indicate significant differences among groups 
(n = 10; p<0.05). 
 
 
Discussion 
Recent studies have provided compelling evidences that the imbalanced 
regulation between the immune system and gut microbiota seems to be involved in 
triggering colitis. Furthermore, modulation of gut microbiota composition can be a key 
target of the prevention and treatment of colitis (5). SCFAs are produced by a bacterial 
fermentation of undigested fiber, and they are known to have a variety of health 
beneficial effects on intestine (21). Polyphenolics are metabolized by gut microbiota in 
colon, and produce a number of metabolites. Polyphenolics and their metabolites can 
influence the composition and function of the gut microbiota and SCFAs production 
(107). In this study, we investigated if the consumption of mango and pomegranate juice 
is capable of modifying the intestinal microbiota and SCFAs production.  
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This study showed that anti-inflammatory activities of mango and juice 
contribute to the prevention and treatment of colitis. Mango and pomegranate juice 
reduced colitis severity, and attenuated the pro-inflammatory cytokines such as TNF, 
IL1, GM-CSF, and IL-6 in mucosal sample, and serum IL-1 and GM-CSF (Figure 
28). 
In the results, pomegranate juice altered microbiota compositions. The genus 
level of Blautia, Fusobacterium, and Ruminococcaceae in feces were induced compared 
to the control group (p<0.05) (Figure 29). Human colonic butyrate producers are mainly 
gram-positive firmicutes, the genera Clostridium, Eubacterium and Faecalibacterium 
(193). Blautia and Ruminococcaceae are involved in the gram-positive bacteria, and they 
have anti-inflammatory effects (194) due to the production of butyrate, which repair the 
epithelium and regulate inflammation (195). Pomegranate juice may induce butyrate 
production through the induction of butyrate producer microbiota, Blautia and 
Ruminococcaceae.  
SCFAs produced by the intestinal bacterial flora have various physiological 
actions involved in health, and it is important to determine the concentrations of fecal 
short-chain fatty acids and evaluate their relationship with large intestinal diseases. 
Butyrate is the most biologically potent of the SCFAs in colon epithelial cells, inhibiting 
human colon carcinoma cell proliferation and inducing apoptosis (196). In our results, 
mango juice significantly induced the amount of isovalerate and valerate compared to 
the control group. Valerate and isovalerate produce from the bacterial fermentation of 
inadequately digested branch chain amino acids. High amounts of these SCFAs suggest 
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the maldigestion of protein (197). In addition, mango juice slightly induced the amount 
of propionate and butyrate also (Figure 30).  
There are several trans-membrane receptors that detect gut microbiota to initiate 
the intercellular response. Gram-negative bacteria containing LPS is a ligand for the 
TLR4/MyD88 receptor (18), and the binding induce the NF-κB signaling pathway. juice 
decreased the expression of TLR4. GPR41 and GPR43 are receptors for SCFAs, and 
they are key regulators of inflammation through the suppression of the NF-κB signaling 
pathway (24). Mango juice increased the expression of GRP43 (Figure 31). The 
modulation of trans-membrane receptors by juice may help to the changes of microbiota 
composition involved in the anti-inflammatory activities.  
 Inflamed cells display the same metabolism that involves a shift from 
mitochondrial oxidative phosphorylation to aerobic glycolysis like tumor cell, which 
known as the Warburg effect (198). SCFAs are used as colonocytes energy sources to 
maintain cell proliferation in normal, non-Warburg cells. However, in cancerous or 
inflamed Warburg cells, SCFAs cannot be used as colonocytes energy sources, are 
accumulated in the cells and trigger autophagy and apoptosis as an HDAC inhibitor 
(199). LDHA produces lactate from glucose and MCT4 is lactate and butyrate 
transporter. The up-regulation of LDHA and down-regulation of MCT4 by juice may 
cause the Warburg effects, and it creates aerobic glycolysis environment and induce 
apoptosis and autophagy by SCFAs (Figure 32).  
The objective of this study was to elucidate whether juice have a significant 
influence on SCFAs and microbiota composition, and whether this would have an 
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influence on autophagy, and markers for energy metabolism. Real time PCR analysis of 
selected representative genus of the intestinal microbiota indicated that polyphenolics 
from pomegranate, but not mango significantly increased genus associated with butyrate 
production. In contrast, mango did not significantly alter the composition of intestinal 
microbiota, however mango juice significantly increased the concentration of valerate 
and isovalerate, while pomegranate juice did not significantly affect the composition of 
SCFAs. Mango and pomegranate juice may mitigate inflammation in DSS-induced 
colitis model in part by altering microbiota composition and SCFAs production.  
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CHAPTER VI  
SUMMARY AND CONCLUSION 
 
Ulcerative colitis is a chronic inflammation of the large intestine, and it may 
increase risk of human colorectal cancer. Therefore, a variety of extensive research has 
been conducted to determine inflammatory mechanisms and to develop the potential 
therapeutic strategies (200). Due to the many possible factors of these disease such as 
genetics, microbiota, and immune dysfunction, colitis remains an important topic of 
research.  
The general scope of this study was to investigate the mechanisms underlying the 
anti-inflammatory properties of mango and pomegranate polyphenols in DSS-induced 
colitis in rats and in LPS-treated treated CCD-18Co, non-cancer colon fibroblasts cell 
lines. In addition, we investigated the differential effects of these polyphenolics on the 
post-transcriptional modulation and the changes of microbiota composition, which 
contribute to the prevention and treatment of colitis. 
This study showed that anti-inflammatory activities of mango and pomegranate 
juice contribute to the prevention and treatment of colitis. Mango and pomegranate juice 
reduced colitis severity, and attenuated the pro-inflammatory cytokines such as TNF, 
IL1, GM-CSF, and IL-6 in mucosal sample, serum IL-1 and GM-CSF, pro-
inflammatory cytokines (TNF- and Il-1) mRNA. In addition, mango and pomegranate 
juice suppressed COX-2 and iNOS mRNA and protein expressions.  
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Our lab has previously shown that polyphenolics, such as pomegranate, wine, 
and betulinic acid, reduced inflammation through the modulation of miRNA expression 
(151, 152, 168). In this study, we evaluated the ability of polyphenolics to the post-
transcriptional modulation. Mango and pomegranate polyphenols were able to 
counteract the expression of HIF-1, which is considered a key regulator of 
inflammation. The mTOR pathway influences the HIF-1 translation. Mango juice 
showed the capacity to suppress the PI3K/AKT/mTOR pathway through the up-
regulation of miRNA-126 in colitis, whereas pomegranate juice suppressed the 
p70S6K1/HIF1pathway through the up-regulation of miRNA-146.  
Polyphenolics in mango and pomegranate differentially affected pathways 
involved in the anti-inflammatory effects. Proteomic and gene expression analysis was 
utilized to determine the potential therapeutic target in prevention of inflammatory 
disease and to elucidate the mechanisms underlying the anti-inflammatory response. 
Results showed that Mango juice decreased the PI3K/AKT-mTOR signaling axis via up-
regulation of miR-126 and let7a, and down-regulation of IR, while pomegranate 
decreased p70S6K by up-regulating miR-145 and down-regulation of the ERK1/2 
pathway. These results suggest that polyphenolics of different predominant structure 
may differentially regulate inflammation-involved pathways while both attenuating 
DSS-induced colitis. This may also indicate that a combination of both juice classes may 
have synergistic effects in mitigation of inflammation. 
Real time PCR analysis of selected representative genus of the intestinal 
microbiota indicated that juice from pomegranate, but not mango, significantly increased 
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genus associated with butyrate production. In contrast, mango did not significantly alter 
the composition of intestinal microbiota, however mango juice significantly increased 
the concentration of valerate and isovalerate, while pomegranate juice did not 
significantly affect the composition of SCFAs. Both mango and pomegranate juice 
seemed to induce Warburg effects through the modulation of the aerobic glycolysis 
components (LDHA and MCT4), and may induce autophagy, possibly through the 
cumulative increase in SCFAs in colonocytes, which serves as an adaptive strategy of 
reducing inflamed cells in inflammation.  
Certain limitations will require further experimentation in the future. The first 
limitation is that juice groups suppress the intestinal inflammation slightly but not 
significantly; however, several inflammatory markers were also evaluated in control, 
mango, and pomegranate juice groups. In addition, the next approach can be to perform 
negative controls (control juice without DSS treatment) to compare the level of intestinal 
inflammation between the negative control and the juice groups. A further limitation is 
that we did not use a semi-purified diet but used rat chow pellets in this study. The chow 
diet typically contains soy protein, so it is not fully known all possible synergistic effects 
of polyphenolics and compounds in the soy protein, such as genistein, on the 
inflammation. In addition, colitis was induced in rats by DSS diluted in the experimental 
juice in this study. However, there can be an association between DSS compounds and 
polyphenolics in the juice, so DSS might not show the same toxicity in the control and 
juice groups. Thus, investigating the detailed interaction among polyphenolics, soy 
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proteins in the chow diet, and DSS compounds, is essential for further understanding the 
effects of mango and pomegranate polyphenolics on colitis. 
In summary, we have investigated the mechanisms underlying the anti-
inflammatory effects of mango and pomegranate juice and potential role of miRNA and 
intestinal microbiota composition in colitis in vivo and in vitro. Mango and pomegranate 
juice exerted anti-inflammatory activities in colitis in vivo and in vitro.  
Overall, this research will provide the scientific basis for comparing the effects of 
different polyphenolics on the mTOR pathway for the anti-inflammatory responses and 
prevention of colitis. In addition, fruit juice can directly influence the post-
transcriptional modification or the intestinal microbiota and its relationship with the 
immune system. The mango and pomegranate polyphenolics are likely a promising 
countermeasure for protection against any potential inflammatory response. 
Additionally, both mango and pomegranate polyphenolics may have synergistic effects 
since both utilize differential molecular mechanism in the mitigation of inflammation.  
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